Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(7-methoxycoumarin-4-yl)-acetyl-KSPLAQA-VRSSSRK(2,4-dinitrophenyl)-NH2 + H2O
?
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-Pro-Leu-Ala-Gln-Ala-Val-[N-3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl]-Arg-Ser-Ser-Ser-Arg-NH2 + H2O
?
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-SPLAQAVRSSSRK-(2,4-dinitrophenyl)-NH2 + H2O
?
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-Ser-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Lys(Dnp)-NH2 + H2O
?
-
-
-
-
?
(EDANS)-ELAQAVRSSSRK-(DABCYL) + H2O
?
TNF-alpha derived substrate
-
-
?
(EDANS)-EPLAQAVRSSSK-(DABCYL) + H2O
?
TNF-alpha derived substrate
-
-
?
26 kDa proTNF-alpha + H2O
17 kDa soluble TNF-alpha + ?
-
-
-
-
?
4',5'-dimethoxyfluoresceinyl-SPLAQAVRSSSR-cys(4-(3-succinimid-1-yl)fluorescein)-NH2 + H2O
?
-
-
-
-
?
7-methoxycoumarin-4-(yl)acetyl-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl-Arg-NH2 + H2O
?
-
an internally quenched peptide substrate is used
-
-
?
7-methoxycoumarin-4-yl-acetyl-Lys-Pro-Leu-Gly-Pro-Leu-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg + H2O
?
-
-
-
-
?
acetyl-SPLAQAVRSSSR-COOH + H2O
acetyl-SPLAQA + VRSSSR-COOH
-
-
-
-
?
Alzheimer's disease amyloid precursor protein + H2O
?
amyloid precursor protein + H2O
soluble amyloid precursor protein alpha fragment + C83
-
-
-
?
amyloid-protein precursor + H2O
?
-
-
-
-
?
angiotensin-converting enzyme type 2 + H2O
?
-
-
-
-
?
angiotensin-converting enzyme-2 + H2O
?
beta-amyloid precursor protein + H2O
?
betacellulin + H2O
?
-
-
-
?
CD16 + H2O
?
substrates CD16a and CD16b are IgG Fc receptors expressed by human natural killer cells and neutrophils, respectively. Substrates contain three separate cleavage sites in close proximity at P1/P1' positions Ala195/Val196, Val196/Ser197, and Thr198/Ile199, revealing a membrane proximal cleavage region in CD16. Mutation S197P effectively blocks CD16a and CD16b cleavage in cell-based assays. Mutant CD16a/S197P is resistant to cleavage when expressed in cells. The S197P mutation does not disrupt IgG binding by the receptor or its activation of NK92 cells by antibody-treated tumor cells
-
-
?
CD16b + H2O
?
human IgG Fc receptor CD16, i.e. FcgammaRIII. CD16b plasma levels are significantly decreased in patients administered a selective inhibitor targeting the metalloproteases ADAM10 and ADAM17. Inhibition of ADAM17 significantly blocks the cleavage of CD16b following neutrophil activation and apoptosis
-
-
?
cell surface VEGF receptor Flt + H2O
?
-
release of an N-terminal extracellular fragment which can antagonize the effects of vascular endothelial growth factor, substrate can be cleaved to release an N-terminal extracellular fragment. Overexpression of ADAM10, EC 3.4.24.81, and ADAM17 increase cleavage while knockdown of ADAM10 and ADAM17 reduce N-terminal cleavage
-
?
cellular prion protein PrPc + H2O
?
-
-
-
-
?
collagen type XVII + H2O
?
-
-
-
-
?
CSF-1 receptor + H2O
?
TACE cleaves the receptor between residues Gln503 and Ser504. Replacement of fourteen residues at the end of the CSF-1 extracellular domain blocks TACE cleavage
-
-
?
discoidin domain receptor 1 + H2O
?
-
-
-
?
Dpa-SPLAQAVRSSSR-NH2 + H2O
?
-
-
-
-
?
endothelial protein C receptor + H2O
?
-
-
-
-
?
epidermal growth factor receptor + H2O
?
-
-
-
-
?
erbB4/HER4 + H2O
?
-
epidermal growth factor, essential function in heart and neural development, TACE is essential for regulated shedding of the HER4 JM-a receptor
-
-
?
FcalphaR + H2O
?
-
i.e. Fc receptor for immunoglobulin A
-
-
?
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser(4O-(beta-D-Gal-(1->3)-alpha-D-GalNAc))-Ser-Lys(DABCYL) + H2O
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala + Val-Arg-Ser-Ser(4O-(beta-D-Gal-(1->3)-alpha-D-GalNAc))-Ser-Lys(DABCYL)
-
-
-
?
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Lys(DABCYL) + H2O
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala + Val-Arg-Ser-Ser-Ser-Lys(DABCYL)
-
-
-
?
glycoprotein Ibalpha + H2O
?
glycoprotein V + H2O
?
-
-
-
-
?
growth factor alpha + H2O
?
-
-
-
-
?
growth hormone binding protein + H2O
?
-
shedding, TACE is critical for PMA-induced GH receptor proteolysis and GHBP generation
-
-
?
growth hormone receptor + H2O
?
-
growth hormone receptor/TACE interaction precedes proteolysis and is transient
-
-
?
HB-EGF heparin binding epidermal growth factor + H2O
?
-
-
-
-
?
heparin-binding EGF-like growth factor + H2O
?
heparin-binding epidermal growth factor-like growth factor + H2O
?
-
-
-
-
?
HER-4 Jma + H2O
?
-
-
-
-
?
IGF-2 receptor + H2O
?
-
-
-
-
?
intercellular adhesion molecule 1 + H2O
soluble intercellular adhesion molecule 1 + ?
-
-
-
?
intercellular adhesion molecule-1 + H2O
?
intercellular cell adhesion molecule-1 + H2O
?
-
-
-
-
?
interleukin (IL)-1R-II + H2O
?
interleukin (IL)-6R + H2O
?
exclusively the extracellular domains of ADAM17 are needed for interaction with substrate, whereas the transmembrane- and cytoplasmic-region are dispensable for this process. In the extracellular part solely the membrane-proximal domain of ADAM17 is mandatory for recognition
-
-
?
interleukin 1 receptor + H2O
?
-
-
-
?
interleukin 1alpha/beta + H2O
?
-
-
-
?
interleukin 6 + H2O
?
-
-
-
?
interleukin 6 receptor + H2O
?
-
-
-
?
interleukin 6 receptor + H2O
soluble interleukin 6 receptor + ?
-
-
-
?
interleukin-1 receptor 2 + H2O
?
-
-
-
-
?
interleukin-1 receptor II + H2O
?
-
-
-
?
interleukin-6 receptor + H2O
?
interleukin-6 receptor + H2O
soluble interleukin-6 receptor + ?
-
-
-
-
?
interleukin-6-receptor + H2O
?
-
-
-
-
?
Jagged protein + H2O
?
-
-
-
-
?
junctional adhesion molecule A + H2O
?
-
-
-
?
LAQAVRSSSR + H2O
?
-
fluorimetric assay for TACE, fluorogenic substrate, a 10-amino-acid peptide capped with an o-aminobenzoyl group on the N-terminal end and with a 3-(2,4-dinitrophenyl)-L-2,3-diaminopropionic amide group on the C-terminal end, enzymatic conversion of the substrate results in a fluorescence enhancement of 11fold
-
-
?
lipoprotein-related protein I + H2O
?
-
lipoprotein-related protein I shedding is significantly decreased in embryonic fibroblast cells lacking ADAM10 and/or ADAM17
-
-
?
lymphotoxin-alpha + H2O
?
-
-
-
-
?
macrophage colony-stimulating factor receptor M-CSFR + H2O
?
-
-
-
-
?
Mca-PLAQAV-Dpa-RSSSR-NH2 + H2O
Mca-PLAQA + V-Dpa-RSSSR-NH2
-
-
-
?
Mca-PLAQAV-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide-RSSSR-NH2 + H2O
?
-
-
-
-
?
Mca-PLAQAVDpa-RSSSR-NH2 + H2O
?
-
-
-
-
?
MHC class I polypeptide-related sequence A + H2O
soluble MHC class I polypeptide-related sequence A + ?
-
-
-
?
MHC class I-related chain + H2O
?
-
i.e. transmembrane protein expressed in pathological conditions, ligands for the activating receptor NKG2D found on cytotoxic lymphocytes. The recruitment of both enzyme and substrate to detergent-resistant membrane microdomains is crucial for efficient proteolysis
-
-
?
N-cadherin + H2O
?
-
-
-
?
nectin-4 + H2O
?
-
-
-
-
?
NH2-LAQAVRSSSR-OH + H2O
?
-
uncapped counterpart of the fluorogenic substrate
-
-
?
Notch 1 + H2O
?
-
ADAM17 is required for Notch1 receptor proteolysis in NSCLC cells in vitro and in vivo
-
-
?
notch 1 receptor + H2O
?
-
-
-
-
?
o-aminobenzoyl-LAQAFRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + FRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
-
enzymatic cleavage 22%
-
-
?
o-aminobenzoyl-LAQAIRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + IRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
-
enzymatic cleavage 66%
-
-
?
o-aminobenzoyl-LAQALRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + LRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
-
enzymatic cleavage 92%
-
-
?
o-aminobenzoyl-LAQAVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + VRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
-
enzymatic cleavage 90%
-
-
?
o-aminobenzoyl-LAQFVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQF + RSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
-
enzymatic cleavage 39%
-
-
?
o-aminobenzoyl-LAQGVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQG + VRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
-
enzymatic cleavage 11%
-
-
?
o-aminobenzoyl-LAQLVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQL + VRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
-
enzymatic cleavage 34%
-
-
?
o-aminobenzoyl-LAQVARSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQVA + RSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
-
enzymatic cleavage 19%
-
-
?
p55 TNF-alpha RI + H2O
?
-
-
-
-
?
p75 neurotrophin receptor + H2O
?
p75 TNF-alpha RII + H2O
?
-
-
-
-
?
p75 tumour necrosis factor receptor + H2O
?
PLAAAVFSS + H2O
PLAAA + VFSS
mutant peptide derived from TNF-alpha, very poor substrate
-
-
?
PLAMAVMSS + H2O
PLAMA + VMSS
mutant peptide derived from TNF-alpha, very poor substrate
-
-
?
PLAQAVRSS + H2O
PLAQA + VRSS
peptide derived from TNF-alpha
-
-
?
pN-collagen I substrate + H2O
?
-
-
-
-
?
preadipocyte factor 1 + H2O
?
pro amphiregulin + H2O
?
-
TACE is capable of cleaving both N- and C-terminal sites in the pro-amphiregulin ectodomain
-
-
?
pro heparin-binding epidermal growth factor + H2O
?
-
purified soluble TACE cleaves a single site in the juxtamembrane stalk of pro heparin-binding epidermal growth factor
-
-
?
Pro-BTC + H2O
?
the cleavage site by ADAM17 is CVVA31-/-DGNS, N-linked glycosylation site is Asn34
-
-
?
pro-EGF receptor + H2O
EGF receptor + ?
-
-
-
-
?
pro-EPR + H2O
?
the cleavage site by ADAM17 is DNPR59-/-VAQV, N-linked glycosylation site is Asn47
-
-
?
pro-HB-EGF + H2O
?
the cleavage site by ADAM17 is RKVR62-/-DLQE, O-linked glycosylation sites are Thr75 and Thr85
-
-
?
pro-interleukin-6 receptor + H2O
interleukin-6 receptor + ?
-
-
-
-
?
pro-L-selectin + H2O
L-selectin + ?
-
-
-
-
?
pro-Notch 1 + H2O
Notch 1 + ?
-
-
-
-
?
pro-TGF-alpha + H2O
mature growth factor
-
-
-
-
?
pro-TGF-alpha + H2O
soluble TGF-alpha + ?
pro-TGFalpha + H2O
?
the cleavage site by ADAM17 is VAAA39-/-VVSH, N-linked glycosylation site is Asn25
-
-
?
pro-TNF-alpha + H2O
soluble TNF-alpha + ?
pro-tumor necrosis factor alpha + H2O
?
with and without a glycan moiety attached, glycosylation increases the enzyme activity. The cleavage site of TNFalpha by ADAM17 is only four residues away from a glycosylated residues, whereas glycosylation occurs 14 residues away from the TGFalpha cleavage site. Cleavage site for ADAM-17 is LAQA76-/-VRSS, O-linked glycosylation site is Ser80
-
-
?
proheparin-binding EGF-like growth factor + H2O
?
-
cleavage occurs between residues RKVR62-DLQE. Substrate shows O-linked glycosylation 13 residues apart from scissile bond
-
?
protein C receptor + H2O
?
-
-
-
-
?
protein tyrosine kinase 7 + H2O
?
-
-
-
?
proTGF-alpha + H2O
soluble TGF-alpha
proTNF-alpha + H2O
soluble TNF-alpha
proTNF-alpha + H2O
soluble TNF-alpha + 9000 Da membrane-bound fragment of TNF-alpha
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha + ?
-
-
-
-
?
protransforming growth factor alpha + H2O
?
-
cleavage occurs between residues AAA39-VVSH. Substrate shows N-linked glycosylation 14 residues apart from scissile bond
-
?
PTP-LAR + H2O
?
-
-
-
-
?
RA175/SynCAM1 + H2O
?
-
neuronal RA175/SynCAM1 isoforms, members of the immunoglobulin family 4, are processed by TACE
-
-
?
receptor tyrosine kinase c-Kit + H2O
?
S80-glycosylated (EDANS)-ELAQAVRSSSRK-(DABCYL) + H2O
?
TNF-alpha derived substrate
-
-
?
S80-glycosylated (EDANS)-EPLAQAVRSSSK-(DABCYL) + H2O
?
TNF-alpha derived substrate
-
-
?
soluble intercellular cell adhesion molecule 1 + H2O
?
-
-
-
?
soluble interleukin 6 receptor + H2O
?
-
-
-
?
soluble TNF + H2O
?
-
-
-
-
?
soluble TNF receptor 1 + H2O
?
-
-
-
-
?
soluble TNF receptor 2 + H2O
?
-
-
-
-
?
soluble TNF-alpha receptor type 1 + H2O
?
-
-
-
-
?
soluble tumor necrosis factor receptor 1 + H2O
?
-
-
-
?
soluble vascular cell adhesion molecule 1 + H2O
?
-
-
-
?
sorCS1c + H2O
?
-
member of the vacuolar protein sorting 10p domain family of neuronal type-I receptors
-
-
?
sorCS2 + H2O
?
-
member of the vacuolar protein sorting 10p domain family of neuronal type-I receptors, minor shedding
-
-
?
sorLA + H2O
?
-
member of the vacuolar protein sorting 10p domain family of neuronal type-I receptors
-
-
?
sortilin + H2O
?
-
member of the vacuolar protein sorting 10p domain family of neuronal type-I receptors, minor shedding
-
-
?
syndecan-4 + H2O
?
-
-
-
?
TGF-alpha + H2O
?
ADAM17, but not related ADAM10, is required for amphiregulin, TGF-alpha, and TNFR1 shedding
-
-
?
TNF receptor 1a + H2O
?
-
-
-
?
TNF-alpha + H2O
soluble TNF-alpha
TRANCE/RANKL + H2O
?
-
-
-
-
?
transferrin receptor protein 1 + H2O
?
-
cleavage occurs between residues ECER100-LAGT. Substrate shows O-linked glycosylation 4 residues apart from scissile bond
-
?
transforming growth factor alpha + H2O
?
transforming growth factor-alpha + H2O
?
-
-
-
-
?
TRP1 + H2O
?
the cleavage site by ADAM17 is ECER100-/-LAGT, O-linked glycosylation sites are: Thr104, Asn251, Asn317, Asn727
-
-
?
tumor necrosis factor alpha + H2O
?
-
-
-
?
tumor necrosis factor alpha receptor I + H2O
?
-
-
-
?
tumor necrosis factor receptor 1 + H2O
?
ADAM17, but not related ADAM10, is required for amphiregulin, TGF-alpha, and TNFR1 shedding
-
-
?
tumour necrosis factor receptor-1 + H2O
?
-
-
-
-
?
tumour necrosis factor receptor-2 + H2O
?
-
-
-
-
?
vascular cellular adhesion molecule-1 + H2O
?
-
-
-
-
?
vasorin + H2O
?
-
-
-
-
?
vasorin + H2O
soluble vasorin + ?
-
-
-
-
?
additional information
?
-
75kDaTNFR2 + H2O
?
-
-
-
-
?
75kDaTNFR2 + H2O
?
-
-
-
-
?
Alzheimer's disease amyloid precursor protein + H2O
?
-
-
-
-
?
Alzheimer's disease amyloid precursor protein + H2O
?
-
TACE is involved in shedding of Alzheimer's disease amyloid precursor protein
-
-
?
amphiregulin + H2O
?
-
-
-
-
?
amphiregulin + H2O
?
-
-
-
?
amphiregulin + H2O
?
ADAM17, but not related ADAM10, is required for amphiregulin, TGF-alpha, and TNFR1 shedding
-
-
?
amphiregulin + H2O
?
-
-
-
-
?
angiotensin-converting enzyme-2 + H2O
?
-
-
-
-
?
angiotensin-converting enzyme-2 + H2O
?
-
ADAM-17 is responsible for the ACE2 shedding
-
-
?
beta-amyloid precursor protein + H2O
?
-
-
-
-
?
beta-amyloid precursor protein + H2O
?
-
shedding
-
-
?
beta-amyloid precursor protein + H2O
?
-
Alzheimer amyloid precursor protein
-
-
?
beta-amyloid precursor protein + H2O
?
-
alpha-secretase processing
-
-
?
beta-amyloid precursor protein + H2O
?
-
APP
-
-
?
beta-amyloid precursor protein + H2O
?
-
-
-
-
?
CD23 + H2O
?
-
-
-
?
CD30 + H2O
?
-
-
-
-
?
CD30 + H2O
?
-
shedding of CD30 upon inhibition of the proteasome is catalyzed by ADAM17
-
-
?
CD44 + H2O
?
-
-
-
?
epiregulin + H2O
?
-
-
-
?
epiregulin + H2O
?
-
-
-
-
?
fractalkine + H2O
?
-
-
-
-
?
fractalkine + H2O
?
-
FK, CX3CL1
-
-
?
fractalkine + H2O
?
-
-
-
-
?
glycoprotein Ibalpha + H2O
?
-
-
-
-
?
glycoprotein Ibalpha + H2O
?
-
ADAM17 is the key enzyme mediating shedding of glycoprotein Ibalpha
-
-
?
glycoprotein Ibalpha + H2O
?
-
-
-
-
?
glycoprotein Ibalpha + H2O
?
-
ADAM17 is the key enzyme mediating shedding of glycoprotein Ibalpha
-
-
?
HB-EGF + H2O
?
-
-
-
?
heparin-binding EGF-like growth factor + H2O
?
-
ADAM17 may be involved in heparin-binding EGF-like growth factor cleavage in response to injury
-
-
?
heparin-binding EGF-like growth factor + H2O
?
-
-
-
-
?
heregulin + H2O
?
-
-
-
?
heregulin + H2O
?
-
-
-
-
?
intercellular adhesion molecule-1 + H2O
?
-
-
-
-
?
intercellular adhesion molecule-1 + H2O
?
-
ADAM-17 mediates shedding of intercellular adhesion molecule-1. The shedding of intercellular adhesion molecule-1 reduces the adhesive capacity of the cells. the cleavage site in the intercellular adhesion molecule-1 is not sequence-specific, but appears to be nonselective
-
-
?
interleukin (IL)-1R-II + H2O
?
-
-
-
?
interleukin (IL)-1R-II + H2O
?
-
-
-
-
?
interleukin (IL)-1R-II + H2O
?
-
-
-
-
?
interleukin (IL)-1R-II + H2O
?
exclusively the extracellular domains of ADAM17 are needed for interaction with substrate, whereas the transmembrane- and cytoplasmic-region are dispensable for this process. In the extracellular part solely the membrane-proximal domain of ADAM17 is mandatory for recognition
-
-
?
interleukin-6 receptor + H2O
?
-
-
-
?
interleukin-6 receptor + H2O
?
the cleavage site by ADAM17 is LPVQ357-/-DSSV, N-linked glycosylation sites are: Asn55, Asn93, Asn221, Asn350
-
-
?
KL-1 + H2O
?
-
-
-
-
?
L-selectin + H2O
?
-
-
-
?
L-selectin + H2O
?
-
-
-
-
?
L-selectin + H2O
?
-
-
-
?
L-selectin + H2O
?
-
shedding
-
-
?
L-selectin + H2O
?
-
regulates plasma membrane composition and releases soluble signaling molecules and receptors from cells
-
-
?
L-selectin + H2O
?
-
-
-
-
?
L-selectin + H2O
?
-
-
-
-
?
L-selectin + H2O
?
-
during early events of death receptor-mediated neutrophil apoptosis, L-selectin downregulation occurs primarily by ADAM17-mediated shedding. During later stages of induced leukocyte apoptosis, soluble L-selectin production occurs independent of ADAM17
-
-
?
L-selectin + H2O
?
-
TACE is involved in cantharidin-induced shedding of L-selectin. Cantharidin induces sustained surface expression and cytoplasmic tail phosphorylation of TACE via p38 MAPK, while L-selectin is involved in promoting protein kinase C-dependent shedding
-
-
?
L-selectin + H2O
?
-
ADAM17 is the main sheddase of the adhesion protein L-selectin
-
-
?
NCAM + H2O
?
-
-
-
?
Notch1 + H2O
?
-
-
-
-
?
Notch1 + H2O
?
-
Notch1 is a substrate for both ADAM10 and ADAM17
-
-
?
p55 TNFR1 + H2O
?
-
-
-
?
p55 TNFR1 + H2O
?
-
-
-
-
?
p55 TNFR1 + H2O
?
-
-
-
-
?
p55 TNFR1 + H2O
?
-
-
-
-
?
p55 TNFR1 + H2O
?
-
-
-
-
?
p75 neurotrophin receptor + H2O
?
-
-
-
-
?
p75 neurotrophin receptor + H2O
?
-
critical role of TACE in ectodomain shedding of the p75 neurotrophin receptor
-
-
?
p75 neurotrophin receptor + H2O
?
-
-
-
-
?
p75 neurotrophin receptor + H2O
?
-
critical role of TACE in ectodomain shedding of the p75 neurotrophin receptor
-
-
?
p75 tumour necrosis factor receptor + H2O
?
-
-
-
-
?
p75 tumour necrosis factor receptor + H2O
?
-
shedding
-
-
?
p75 tumour necrosis factor receptor + H2O
?
shedding
-
-
?
p75 tumour necrosis factor receptor + H2O
?
-
-
-
-
?
p75 tumour necrosis factor receptor + H2O
?
-
-
-
-
?
p75 tumour necrosis factor receptor + H2O
?
-
shedding
-
-
?
p75 tumour necrosis factor receptor + H2O
?
-
shedding
-
-
?
p75 tumour necrosis factor receptor + H2O
?
-
-
-
-
?
p75 tumour necrosis factor receptor + H2O
?
-
-
-
-
?
preadipocyte factor 1 + H2O
?
-
-
-
-
?
preadipocyte factor 1 + H2O
?
-
TACE is the major protease responsible for conversion of membrane-bound Pref-1 to the biologically active diffusible form
-
-
?
pro-TGF-alpha + H2O
soluble TGF-alpha + ?
-
-
-
?
pro-TGF-alpha + H2O
soluble TGF-alpha + ?
-
-
-
-
?
pro-TNF-alpha + H2O
soluble TNF-alpha + ?
-
-
-
?
pro-TNF-alpha + H2O
soluble TNF-alpha + ?
-
-
-
-
?
pro-TNF-alpha + H2O
soluble TNF-alpha + ?
-
-
-
?
pro-TNF-alpha + H2O
soluble TNF-alpha + ?
-
-
-
-
?
proTGF-alpha + H2O
soluble TGF-alpha
-
-
-
-
?
proTGF-alpha + H2O
soluble TGF-alpha
the membrane-proximal domain in the extracellular part of ADAM17 is mandatory for recognition of the type-I transmembrane proteins, but not for the interaction with the type-II transmembrane molecule TNF-alpha
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
638993, 638994, 638995, 638996, 638997, 638998, 638999, 639000, 639001, 639002, 639003, 639004, 639005, 639006, 639007, 639008, 639009, 639010, 639011, 639012, 639013, 677450, 679641, 681665, 682211, 682570, 682629, 719165 -
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
release of proTNFalpha from cellular membranes
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
release of membrane-bound TNF-alpha
?
proTNF-alpha + H2O
soluble TNF-alpha
-
cleavage occurs between residues LAQA76-VRSS. Substrate shows O-linked glycosylation 4 residues apart from scissile bond
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
membrane-bound tumor necrosis factor alpha undergoes proteolysis
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
638979, 638980, 638981, 638983, 638984, 638987, 638988, 638991, 638992, 638994, 638995, 639000, 639001, 639002, 639003, 639004, 639006, 639010, 639011, 639012, 639013, 679671, 681016 -
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha
-
-
-
-
?
receptor tyrosine kinase c-Kit + H2O
?
-
-
-
-
?
receptor tyrosine kinase c-Kit + H2O
?
-
ADAM-17 controls mast cell survival by regulating shedding and surface expression of c-Kit
-
-
?
sorCS3 + H2O
?
-
member of the vacuolar protein sorting 10p domain family of neuronal type-I receptors
-
-
?
syndecan-1 + H2O
?
-
-
-
?
syndecan-1 + H2O
?
both ADAM10 and ADAM17 contribute to SDC1 shedding
-
-
?
TNF-alpha + H2O
?
-
-
-
?
TNF-alpha + H2O
?
-
ranitidine enhances TNF-alpha production after lipopolysaccharide treatment through augmented p38 activation, and this seems to occur through TACE
-
-
?
TNF-alpha + H2O
?
-
-
-
-
?
TNF-alpha + H2O
soluble TNF-alpha
-
-
-
-
?
TNF-alpha + H2O
soluble TNF-alpha
-
membrane-bound tumor necrosis factor alpha undergoes proteolysis
-
-
?
TNF-alpha + H2O
soluble TNF-alpha
-
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
638993, 638994, 638995, 638996, 638997, 638998, 638999, 639000, 639001, 639002, 639003, 639004, 639005, 639006, 639007, 639008, 639009, 639010, 639011, 639012, 639013 -
-
?
transforming growth factor alpha + H2O
?
-
-
-
?
transforming growth factor alpha + H2O
?
-
TGF alpha shedding
-
-
?
transforming growth factor alpha + H2O
?
-
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
638979, 638980, 638981, 638983, 638984, 638987, 638988, 638991, 638992, 638994, 638995, 639000, 639001, 639002, 639003, 639004, 639006, 639010, 639011, 639012, 639013 -
-
?
transforming growth factor alpha + H2O
?
-
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
-
-
?
transforming growth factor alpha + H2O
?
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
TACE is a multidomain, type I transmembrane protein, contains a pro-domain which is removed by proteolysis to generate the active enzyme and a zinc-dependent metalloprotease catalytic domain, TACE cleaves peptides containing the sequence of the processing site at the physiolocically relevant peptide bond
-
-
?
additional information
?
-
TACE is a multidomain, type I transmembrane protein, contains a pro-domain which is removed by proteolysis to generate the active enzyme and a zinc-dependent metalloprotease catalytic domain, TACE cleaves peptides containing the sequence of the processing site at the physiolocically relevant peptide bond
-
-
?
additional information
?
-
-
o-aminobenzoyl-LAQVARSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl diaminopropionic amide is no substrate
-
-
?
additional information
?
-
-
4-dinitrophenyl)-L-2,3-diaminopropionyl diaminopropionic amide-PChaGC(Me)HK(NMA)-NH2 is not cleaved at all by TACE
-
-
?
additional information
?
-
-
amphiregulin is no substrate
-
-
?
additional information
?
-
-
TACE is the only enzyme confirmed to process TNF-alpha in vitro and in vivo
-
-
?
additional information
?
-
-
ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17
-
-
?
additional information
?
-
-
TACE is not involved in shedding of angiotensin converting enzyme
-
-
?
additional information
?
-
-
TACE may have a role in phorbol myristate acetate-induced shedding of epiregulin
-
-
?
additional information
?
-
-
a comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme
-
-
?
additional information
?
-
-
protein in the absence of salt or inhibitor shows a rapid and specific autocleavage between residues Y352-V353 which resides within the surrounding sequence TLGLAYVGSPRN
-
-
?
additional information
?
-
affinity for TACE is measured by an internally quenched peptide substrate with its sequence derived from the pro-TNF-alpha cleavage site using a catalytic domain of recombinant human TACE enzyme
-
-
?
additional information
?
-
analysis of ADAM cognate substrates reveals that glycosylation is often present in the vicinity of the scissile bond
-
-
?
additional information
?
-
high throughput screening assays are developed using glycosylated and non-glycosylated substrate, and positional scanning, substrate specificity, overview
-
-
?
additional information
?
-
mutations at the P2 site and the P2' site of the substrate peptide largely affect the peptide cleavage efficiency in the enzymaticassay. The P2/P2'sites may affect the efficiency of the conformation search for the correct peptide orientation, which in turn affects the substrate cleavage efficiency. Peptide PRYEA?YKMG is not a substrate
-
-
?
additional information
?
-
noncatalytic domains of ADAM17 do not directly bind to TNF-alpha derived substrates used but affect the binding nevertheless, most likely because of steric hindrance. Noncatalytic domains of ADAM17 affect the size/shape of the carbohydrate-binding pocket contained within the catalytic domain of ADAM17. Protease shows significantly decreased activity when the TNF-alpha-derived sequence is induced into alpha-helical conformation
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
angiotensin converting enzyme is not cleaved by TACE
-
-
?
additional information
?
-
-
in mice, the interleukin-6 receptor is not a target of ADAM17
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
TACE-mediated ectodomain shedding of erbB ligands, epitomized by TGFalpha is a key component of the neuron-to-glia signaling mechanism used by excitatory amino acids to facilitate the advent of female puberty
-
-
?
additional information
?
-
-
compounds are assessed in two cellular assays, the human peripheral blood mononuclear cell assay (PBMC) and the human whole blood assay (WBA), for their ability to suppress the formation of TNF-alpha brought about by lipopolysaccharide (LPS) stimulation. Success in the PBMC assay relies on the ability of the inhibitor to penetrate into the cells, thus enabling it to inhibit TACE and thereby to suppress the release of intracellular, soluble TNF-alpha. In the WBA, compounds must also have the ability to penetrate cells
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,2R)-2-(3-phenoxylphenyl)-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
(1R,2R)-2-trans-carboisopropoxyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
(1R,2R)-2-trans-N-benzylaminocarbonyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
(1R,2R)-2-[3-(3,4-dichlorobenzyloxy)phenyl]-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
(1R,2R)-N-hydroxy-2-[(4-methylpiperazin-1-yl)carbonyl]-2-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxamide
-
-
(1R,2R)-N1-benzyl-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N1-cyclohexyl-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]-N1-phenylcyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N2-hydroxy-N1,N1-dimethyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-(3-fluoro-4-[[2-(1-methyl-1H-pyrazol-5-yl)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
(1R,2S)-1-(3-fluoro-4-[[2-(methylamino)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
(1R,2S)-1-[3-fluoro-4-[(2-morpholin-4-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxy-N1,N1-dimethylcyclopropane-1,2-dicarboxamide
-
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
(1R,2S)-1-[3-fluoro-4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
(1R,2S)-1-[3-fluoro-4-[(2-pyrrolidin-1-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
(1R,2S)-1-[4-(benzyloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
(1R,2S)-N2-hydroxy-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N1-(piperidin-4-ylmethyl)cyclopropane-1,2-dicarboxamide
-
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
(1R,2S)-N2-hydroxy-N1-methyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1S,2R)-2-[[(3R)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
(1S,2R)-2-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
(1S,2R)-N-hydroxy-2-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
(1S,2R)-N-hydroxy-2-[[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
(1S,2R)-N-hydroxy-2-{4-[(2-imino-1,2-dihydroquinolin-4-yl)methoxy]benzyl}-2-(methoxycarbonyl)cyclopropanecarboximidic acid
-
-
(1S,2S)-2-((S)-cyano(4-((2-phenylquinolin-4-yl)methoxy)phenyl)methyl)-N-hydroxycyclopropanecarboxamide
-
(2R)-5-nitroguanyl-2-([(2R,3S)-2-(cyclohexylmethyl)-3-cyclopropyl-3-[formyl(hydroxy)amino]propanoyl]-amino)-N-(1,3-thiazol-2-yl)pentanamide
(2R)-N-hydroxy-2-(7-methoxy-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl)-3-methylbutanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(4-methylcyclohexyl)-methyl]hexanamide
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(5-methyl-2-thienyl)methyl]hexanamide
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutyl-4-methylpentanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutyl-4-methylpentanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-6,6,6-trifluoro-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-3-[formyl(hydroxy)amino]hexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-6,6,6-trifluoro-3-[formyl(hydroxy)amino]hexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-[(1S)-1-[formyl(hydroxy)amino]-2-phenylethyl]-4-methylpentanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[5-methyl-2-thienylmethyl]hexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]hexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
(2R,3S)-N-[(1S,2R)-4-nitroguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-{(1R)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl}-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2S)-2-amino-5-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-N-(1,3-thiazol-2-yl)pentanamide hydrochloride
(2S)-2-[(tert-butoxycarbonyl)amino]-5-({(Z)-(methyl-sulfanyl)[(methylsulfonyl)imino]methyl}amino)pentanoic acid
(2S,3R)-2-[(tert-butoxycarbonyl)amino]-5-{[imino(2-oxido-2-oxohydrazino)methyl]amino}-3-methylpentanoic acid (3R) Nalpha-boc-Ngamma-nitro-3-methyl L-arginine
(2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-5-({(Z)-(methylsulfanyl)[(methylsulfonyl)imino]methyl}-amino)pentanoic acid
(2S,3R)-5-methanesulfonylguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
(2S,3R)-5-nitroguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
(3R,4R)-4-([[4-(1,3-dihydrofuro[3,4-b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-([[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-([[4-(2,3-dihydrofuro[2,3-b]quinolin-4-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[([4-[(2,3-dimethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[([4-[(2-cyclopropylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[([4-[(2-ethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[([4-[(3-ethyl-2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[[(4-[[2-(dimethylamino)quinolin-4-yl]methyl]phenyl)carbonyl]amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[([4-[(2-morpholin-4-ylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[([4-[(3-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[[(4-[[2-(1-methylethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[[(4-[[2-(trifluoromethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4S)-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
-
-
(3R,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
-
-
(3S)-1-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]pyrrolidine-3-thiol
-
-
(3S)-4-[[4-(but-2-ynylamino)phenyl]sulfonyl]-N-hydroxy-2,2-dimethylthio-morpholine-3-carboxamide
-
-
(3S,4R)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-3-carboxamide
-
-
(3S,4S)-1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-(2,2-dimethylpropyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-(butylsulfonyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-(furan-2-ylmethyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-acetyl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-but-2-yn-1-yl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-cyclobutyl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-tert-butyl-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
-
-
(3S,4S)-1-[2-(dimethylamino)ethyl]-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
-
-
(3S,4S)-3-[([4-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-3-[([4-[(2-ethyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-3-[([4-[(2-ethylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-3-[([4-[(2-tert-butylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(1-methylethyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(2-methylprop-2-en-1-yl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(2-methylpropanoyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
substance exhibits excellent oral bioavailability in pharmacokinetic studies
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-phenylpyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-prop-2-en-1-ylpyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]pyrrolidine-3-carboxamide
-
-
(4-bromobut-2-enyloxymethyl)benzene
-
-
(4-methoxyphenyl)acetic acid 4-benzyloxybut-2-enyl ester
-
-
(5R)-4-(2-((1R,3R)-adamantan-1-yl)ethyl)-5-(4-hydroxybenzyl)-1-((2R)-1-(2-(((R)-6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl)-methyl)pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl)piperazine-2,3-dione
-
(5R)-5-(2',4'-difluorobiphenyl-4-yl)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-(4'-chlorobiphenyl-4-yl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[2'-(1-methyl-1H-tetrazol-5-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(trifluoromethyl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(quinolin-6-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[3'-(2-methyl-1,3-thiazol-4-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(1H-pyrazol-3-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1,3-thiazol-2-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methyl-2H-indazol-6-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methylpyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(3-phenyl-1,2-oxazol-5-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(4-methyl-2,5-dioxoimidazolidin-4-yl)phenyl]imidazolidine-2,4-dione (non-preferred name)
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrazin-2-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-2-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrimidin-5-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[4-(2-aminopyridin-4-yl)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-[4-(5-chloro-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R,6R)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4-dioxo-1,3-diazaspiro[4.4]nonane-6-carboxamide
-
-
(5R,6S)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4-dioxo-1,3-diazaspiro[4.4]nonane-6-carboxamide
-
-
(5R,7S,8R)-N-hydroxy-8-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-oxaspiro[4.4]nonane-7-carboxamide
-
-
(5S)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)-methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)-4-(2-phenylbutyl)piperazine-2,3-dione
-
(5S)-4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[(2S)-1-(2-[[(6S)-6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
90% inhibition at 0.04 mM
(5S)-5-(4-fluorophenyl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5S)-5-(4-hydroxybenzyl)-1-[(2S)-1-(2-[[(6S)-6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[2-(tricyclo[3.3.1.13,7]dec-1-yl)ethyl]piperazine-2,3-dione
95% inhibition at 0.04 mM
(5S,6R)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4-dioxo-1,3-diazaspiro[4.5]decane-6-carboxamide
-
-
(5S,6S)-N-hydroxy-5-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-2,3,5,6-tetrahydro-4aH-cyclopenta[b][1,4]dioxine-6-carboxamide
-
-
(5S,7S,8R)-N-hydroxy-8-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-oxaspiro[4.4]nonane-7-carboxamide
-
-
(7S,8R)-N-hydroxy-8-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1,4-dioxaspiro[4.4]nonane-7-carboxamide
-
-
(R)-4-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
(R)-4-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(naphthalen-2-ylmethyl)piperazine-2,3-dione
-
(R)-4-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-5-(naphthalen-2-ylmethyl)piperazine-2,3-dione
-
(R)-4-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)-5-(4-hydroxybenzyl)-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-piperazine-2,3-dione
-
(S)-1((R)-1((S)-2-(((S)-6-benzyl-2,3-dioxopiperazin-1-yl)methyl)-pyrrolidin-1-yl)-3-cyclohexylpropan-2-yl)-5-(4-hydroxybenzyl)-4-phenethylpiperazine-2,3-dione
-
(S)-4-((3S,5S,7S)-adamantan-1 -ylmethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
(S)-4-((4-(tert-butyl)cyclohexyl)methyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(naphthalen-2-ylmethyl)piperazine-2,3-dione
-
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-5-(naphthalen-2-ylmethyl)piperazine-2,3-dione
-
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-5-(4-hydroxybenzyl)-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-piperazine-2,3-dione
-
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-5-butyl-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)piperazine-2,3-dione
-
(S)-4-(2-(adamantan-1-yl)ethyl)-5-butyl-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)piperazine-2,3-dione
-
(S)-4-(2-(adamantan-1yl)ethyl)-1-((S)-1-((S)-2-(((S)-6-benzyl-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-phenylpropan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
(S)-4-(cyclobutylmethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
(S)-4-(cyclohexylmethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
(S)-4-(cyclopentylmethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
(S)-5-benzyl-1-((R)-1-((S)-2-(((S)-6-benzyl-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-cyclohexylpropan-2-yl)-4-phenethylpiperazine-2,3-dione
-
(S)-5-benzyl-1-((R)-1-cyclohexyl-3-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-4-phenethylpiperazine-2,3-dione
-
1,25-dihydroxyvitamin D
-
1,25-dihydroxyvitamin D inhibition of TACE is a potential common mechanism underlying the efficacy of therapy with 1,25-dihydroxyvitamin D or its analogs to improve outcomes in chronic kidney disease. 1,25-dihydroxyvitamin D prevents/moderates not only the onset and progression of parathyroid TACE/TGFalpha-driven secondary hyperparathyroidism, but renal TACE/TGFalpha-driven fibrotic and inflammatory lesions to the renal parenchyma, and TACE/TNFalpha-driven systemic inflammation
1-(1,3-benzoxazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
-
-
1-(1H-benzimidazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
-
-
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
-
-
1-(2,2-dimethylpropyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-(butylsulfonyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-but-2-yn-1-yl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-ethylpropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
1-methyl-2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
1-methylethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
1-methylethyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
1-methylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
1-[(4-acetylpiperazin-1-yl)sulfonyl]-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
-
-
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
-
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
-
1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]-1,3,5-triazinane-2,4,6-trione
-
IC50: 0.0073 mM
13-[(4R)-2,5-dioxoimidazolidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]tridecanamide
-
-
2(R)-benzyloxymethyl-N-(2,2-dimethyl-1(S)-methyl-carbamoylpropyl)-3-(S)-(4-methoxyphenyl)succinamic acid
-
-
2,6-anhydro-3,4,5-trideoxy-1-(hydroxyamino)-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-D-threo-hexose
-
-
2-(3-benzyloxyphenyl)-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
2-(6-methyl-2-oxo-2H-chromen-3-ylmethyl)-pent-4-enoic acid hydroxyamide
-
-
2-benzyl-N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
-
-
2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
2-[(5R,6R)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]acetamide
-
-
2-[(5R,6S)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]acetamide
-
-
2-[3-(2-methylquinolin-4-yl)methoxylphenyl]-2-trans-carboxamidocyclopropane hydroxyamic acid
-
-
2-[3-(2-methylquinolin-4-yl)methoxyphenyl]-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]acetamide
-
IC50: above 0.1 mM
2-[[4-(but-2-yn-1-ylamino)phenyl]sulfonyl]ethanethiol
-
-
2-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]ethanethiol
-
-
2-[[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl](methyl)amino]-N-hydroxyacetamide
-
-
3(R)-benzyloxymethyl-2-(S)-(4-methoxyphenyl)pent-4-enoic acid
-
-
3(R)-benzyloxymethyl-2-(S)-(4-methoxyphenyl)pent-4-enoic acid (2,2-dimethyl-1-(S)-methylcarbamoylpropyl)amide
-
-
3-(6-bromo-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
-
-
3-(6-chloro-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
-
-
3-(6-tert-butyl-2-oxo-2H-chromen-3-yl)-N-hydroxypropanamide
-
-
3-([[4-(1,3-dihydrofuro[3,4-b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-([[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-([[4-(2,3-dihydrofuro[2,3-b]quinolin-4-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(2,3-dimethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(2-cyclopropylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(2-ethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(3-ethyl-2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoic acid
-
-
3-[[(4-[[2-(dimethylamino)quinolin-4-yl]methyl]phenyl)carbonyl]amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[[4-(but-2-yn-1-ylamino)phenyl]sulfonyl]cyclohexanethiol
-
-
3-[[4-(but-2-yn-1-ylamino)phenyl]sulfonyl]propane-1-thiol
-
-
3-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]cyclohexanethiol
-
-
3-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]cyclopentanethiol
-
-
3-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]propane-1-thiol
-
-
4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxamide
-
-
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
-
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-benzoyl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-butyryl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(propane-2-sulfonyl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-isobutyryl-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-pyridin-4-ylmethyl-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-1,4-dicarboxylic acid 1-diethylamide 4-hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
-
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-(dimethylsulfamoyl)-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dichlorothiophen-3-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dimethyl-1,3-thiazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)carbonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)methyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(5-chlorothiophen-2-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(morpholin-4-ylsulfonyl)piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(piperidin-1-ylsulfonyl)piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(pyrrolidin-1-ylsulfonyl)piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-2-ylpiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-4-ylpiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[(2-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
-
-
4-[(2-methylquinolin-4-yl)methoxy]-N-(1,3,5-trioxo-2,4-diazaspiro[5.5]undec-7-yl)benzamide
-
IC50: 0.000138 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)benzamide
-
IC50: above 0.1 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-2-oxa-7,9-diazaspiro[4.5]dec-4-yl)benzamide
-
IC50: 0.000044 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-7,9-diazaspiro[4.5]dec-1-yl)benzamide
-
IC50: 0.000024 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-([2,4,6-trioxo-5-[1-(tetrahydro-2H-pyran-2-yl)piperidin-4-yl]hexahydropyrimidin-5-yl]methyl)benzamide
-
-
4-[(2-methylquinolin-4-yl)methoxy]-N-([2,4,6-trioxo-5-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]hexahydropyrimidin-5-yl]methyl)benzamide
-
IC50: 0.000031 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-([2,4,6-trioxo-5-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]hexahydropyrimidin-5-yl]methyl)benzamide
-
IC50: 0.00001 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-([5-[1-(methylsulfonyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)benzamide
-
IC50: 0.000029 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-([5-[4-(methylsulfonyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)benzamide
-
IC50: 0.000002 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[(2,4,6-trioxo-5-phenylhexahydropyrimidin-5-yl)methyl]benzamide
-
-
4-[(2-methylquinolin-4-yl)methoxy]-N-[(2,4,6-trioxo-5-piperidin-4-ylhexahydropyrimidin-5-yl)methyl]benzamide
-
IC50: 0.000055 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-yl)methyl]benzamide
-
IC50: 0.00236 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]benzamide
-
IC50: 0.000026 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[2-(methylsulfonyl)-6,8,10-trioxo-2,7,9-triazaspiro[4.5]dec-4-yl]benzamide
-
IC50: 0.000036 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[6,8,10-trioxo-2-(pyridin-3-ylcarbonyl)-2,7,9-triazaspiro[4.5]dec-4-yl]benzamide
-
IC50: 0.000029 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[[2,4,6-trioxo-5-(4-phenylpiperazin-1-yl)hexahydropyrimidin-5-yl]methyl]benzamide
-
-
4-[([4-[(1,1-dimethylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)methyl]-N-hydroxy-1-(isopropylsulfonyl)piperidine-4-carboxamide
-
-
4-[2-(hydroxyamino)-2-oxoethyl]-N,N-dimethyl-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-1-carboxamide
-
-
4-[4-(4-hydroxy-but-2-ynylamino)-benzenesulfonylmethyl]-4-hydroxycarbamoyl-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide
5-(4-acetylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.00062 mM
5-(4-benzylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000195 mM
5-(4-hexylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000081 mM
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
-
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamanylpropyl]piperazine-2,3-dione
-
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
-
5-(4-methylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000091 mM
5-methyl-5-(2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]ethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.049 mM
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-3-oxopropyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.0008 mM
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.011 mM
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]propyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: above 0.1 mM
5-methyl-5-[(2E)-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]prop-2-en-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.0022 mM
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenoxy]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.0013 mM
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]dihydropyrimidine-2,4(1H,3H)-dione
-
IC50: 0.0037 mM
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.00103 mM
5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-phenylimidazolidine-2,4-dione
-
-
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(2-phenoxyphenyl)imidazolidine-2,4-dione
-
-
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(3-phenoxyphenyl)imidazolidine-2,4-dione
-
-
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-oxopyrrolidin-1-yl)phenyl]imidazolidine-2,4-dione
-
-
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(morpholin-4-yl)phenyl]imidazolidine-2,4-dione
-
-
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yloxy)phenyl]imidazolidine-2,4-dione
-
-
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrrolidin-1-ylcarbonyl)phenyl]imidazolidine-2,4-dione
-
-
5-[4-(1-methylethyl)piperazin-1-yl]-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000096 mM
5-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.00054 mM
5-[4-(2,2-dimethylpropyl)piperazin-1-yl]-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.00016 mM
5-[4-(cyclopentyloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
5-[4-(isoquinolin-7-yloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-(pyridin-3-ylcarbonyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000535 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-piperazin-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.0011 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-piperidin-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000855 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(2-phenylethyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000084 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(3-phenylpropyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.00011 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(4-nitrophenyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.0028 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000275 mM
7-(1-methyl-2,5-dioxoimidazolidin-4-yl)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
7-(2,5-dioxoimidazolidin-4-yl)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
7-(3-methyl-2,5-dioxoimidazolidin-4-yl)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
7-[(4R)-2,5-dioxoimidazolidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
7-[(4S)-2,5-dioxoimidazolidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
APMA
-
inhibits TACE completely
benzyl (1S,2R)-4-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
cyclohexyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
cyclohexylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
cyclopentyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
cyclopropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
Cys-Gln-Val
-
tripeptide Cys-Gln-Val shows about 50%, 30% and 25% residual activity at 0.0005, 0.00005 and 0.000005 mM, respectively
DPC333
-
specific inhibitor
EGTA
-
1 mM, treatment of cells dramatically inhibits shedding of shedding of FcalphaR, i.e. Fc receptor for immunoglobulin A
ethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
ethyl (1R,2S)-1-[3-bromo-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
ethyl (1R,2S)-1-[3-chloro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
ethyl (1R,2S)-1-[3-fluoro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
ethyl (1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-phenoxybenzyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(2-methylpropyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(trifluoromethyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylpyridin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
gelastatin hydroxamate
-
-
Gln-Cys-Ala
-
tripeptide Gln-Cys-Ala shows about 35%, 20% and 22% residual activity at 0.0005, 0.00005 and 0.000005 mM, respectively
Gln-Cys-Val
-
tripeptide Gln-Cys-Val shows about 45%, 28% and 10% residual activity at 0.0005, 0.00005 and 0.000005 mM, respectively
Gln-Val-Cys
-
tripeptide Gln-Val-Cys shows about 59%, 40% and 8% residual activity at 0.0005, 0.00005 and 0.000005 mM, respectively
IC-3
-
protects TACE from degradation by inhibiting either TACE itself or another metalloprotease
L-NG-(2-pyridylsulfonyl)arginine2-aminothiazole amide hydochloride
L-NG-nitroarginine 2-aminothiazole amide dihydrochloride
lomofungin
15% residual activity at 0.0125 mM, 6% residual activity at 0.05 mM, 0.03% residual activity at 0.1 mM
macrocyclic hydroxamic acid
methyl (1R,2R)-1-[3-(2-[3-[(1Z)-buta-1,3-dien-1-yl]phenyl]ethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-(benzyloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-(but-2-yn-1-yloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-(cyclohexylmethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-[(4-chlorobenzyl)oxy]phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-methoxyphenyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[3-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[4-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-naphthalen-2-ylethoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-phenylethoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(4-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-ylmethoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-yloxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(3-methoxybenzyl)oxy]phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-(benzyloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-(cyclohexylmethoxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-[(2-chlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-[(3,4-dichlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-1-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-2-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
methyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
methyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
methyl (5R)-5-{7-[(3,5-diethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate
-
-
methyl (5R)-5-{7-[(3,5-dimethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate
-
human whole blood assay: 31% inhibition
methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazin-1-ylcarbonyl)-5-azaspiro[2.5]octane-5-carboxylate
i.e. INCB7839, selective inhibitor of endopeptidases ADAM-10 and ADAM-17
methyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
methyl 4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxylate
-
-
methyl 4-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,5-dioxoimidazolidine-4-carboxylate
-
IC50: 0.0047 mM
N(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-alanine amide
N-(2-acetyl-6,8,10-trioxo-2,7,9-triazaspiro[4.5]dec-4-yl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000055 mM
N-(8-acetyl-1,3,5-trioxo-2,4,8-triazaspiro[5.5]undec-11-yl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-([5-[1-(1-methylethyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000052 mM
N-([5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000013 mM
N-([5-[4-(1-methylethyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000007 mM
N-([5-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000029 mM
N-([5-[4-(5-amino-8-carbamimidamido-4-oxooctyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-2(R)-(6-methoxy-1,1-dioxo-3,4-dihydro-1H-1-benzo[1,2,4]thiadiazin-2-yl)propionamide
-
-
N-hydroxy-2(R)-[2,3,4,5-tetrahydrobenzo[1,2,5-f]-thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(2,6-methylpyridyl-4-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propanamide
-
human whole blood assay: 37% inhibition
N-hydroxy-2(R)-[7-(2-trifluromethylphenyl)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide
-
-
N-hydroxy-2(R)-[7-(3,5-dichlorobenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 12% inhibition
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
-
human whole blood assay: 17% inhibition
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide
-
human whole blood assay: 0% inhibition
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 26% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine 1,1-dioxide]-6-N-(methanesulfonyl)hexylamide
-
-
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
-
human whole blood assay: 11% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide
-
human whole blood assay: 0% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide
-
human whole blood assay: 16% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-aminohexylamidetrifluoroacetic acid salt
-
human whole blood assay: 3% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-N-[(1,1-dimethylethoxy)carbonyl]hexylamide
-
human whole blood assay: 3% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(3,5-dimethylbenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 2% inhibition
N-hydroxy-2(R)-[7-(3-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(4,5-dimethylthiazolyl-2-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
-
human whole blood assay: 0% inhibition
N-hydroxy-2(R)-[7-(4-methoxyphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(4-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(4-phenylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(4-trifluoromethylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 58% inhibition
N-hydroxy-2(R)-[7-(N-3,5-dimethylbenzoylamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propylamide
-
-
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide
-
human whole blood assay: 39% inhibition
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 30% inhibition
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide
-
human whole blood assay: 20% inhibition
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 21% inhibition
N-hydroxy-2(R)-[7-methoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-N-(3,5-dimethoxymethyleneamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide
-
human whole blood assay: 3% inhibition
N-hydroxy-2(R)-[7-phenoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-phenyl-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide
-
-
N-hydroxy-2-((6-methoxy-2H-chromen-3-yl)methyl)propanamide
-
-
N-hydroxy-2-(2-oxo-2H-chromen-3-yl)acetamide
-
-
N-hydroxy-2-methyl-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
-
-
N-hydroxy-2-[2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide
-
-
N-hydroxy-2-[7-methoxy-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide
-
-
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
-
-
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)propanamide
-
-
N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)propanamide
-
-
N-hydroxy-3-[([4-[(2-morpholin-4-ylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
-
-
N-hydroxy-3-[([4-[(3-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
-
-
N-hydroxy-3-[[(4-[[2-(trifluoromethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-2-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-(methylsulfonyl)piperidine-4-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-propylpiperidine-4-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]tetrahydro-2H-pyran-4-carboxamide
-
-
N-[(1R,2S)-2-(hydroxycarbamoyl)-4-oxocyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1R,2S)-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1R,2S)-4,4-difluoro-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1R,2S)-4-aziridin-1-yl-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1R,2S)-4-hydroxy-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1S,2R)-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(4-methyl-2,5-dioxoimidazolidin-4-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(4S,5S,7R)-2-[7-(1-benzylpiperidin-4-yl)]methylcarbamoyl-5-hydroxy-2-methyloct-4-yl]-N'-[(R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]isophthalamide
-
-
N-[(5-benzyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000018 mM
N-[(5-ethyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000016 mM
N-[(5R,6R)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(5R,6R)-2,4-dioxo-1,3-diazaspiro[4.5]dec-6-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(5R,6S)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(5R,9R)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(5R,9R)-7-(2-methylpropanoyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(1,1-dimethylprop-2-yn-1-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2,2-dimethylpropanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2,2-dimethylpropyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2,5-dioxoimidazolidin-4-yl)ethyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2-fluoroethyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(3,3-dimethylbutanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(4,5-dihydro-1,3-thiazol-2-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-acetyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-ethyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-tert-butyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-[2-(ethylsulfonyl)ethyl]-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-[2-(hydroxyamino)-2-oxoethyl]cyclohexyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-[2-(hydroxyamino)-2-oxoethyl]cyclohexyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
N-[2-(2,2-dimethylpropanoyl)-6,8,10-trioxo-2,7,9-triazaspiro[4.5]dec-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000111 mM
N-[2-(hydroxycarbamoyl)cyclobutyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
N-[4-(hydroxyamino)-4-oxo-2-(phenylsulfanyl)butyl]-3-(naphthalen-2-yl)-L-alanyl-N-(2-{[(benzyloxy)carbonyl]amino}ethyl)-L-alaninamide
-
peptidomimetic inhibitor, 54.5% inhibition in in vitro lipopolysaccharide cytotoxicity tests, inhibitory activity in vivo by measuring the expression of mTNFalpha
N-[4-(hydroxyamino)-4-oxo-2-(phenylsulfanyl)butyl]-L-phenylalanyl-N-(2-{[(benzyloxy)carbonyl]amino}ethyl)-L-alaninamide
-
peptidomimetic inhibitor, 54.5% inhibition in in vitro lipopolysaccharide cytotoxicity tests
N-[4-(hydroxyamino)-4-oxo-2-(propan-2-ylsulfanyl)butyl]-L-phenylalanyl-N-(2-{[(benzyloxy)carbonyl]amino}ethyl)-L-alaninamide
-
peptidomimetic inhibitor, 27.3% inhibition in in vitro lipopolysaccharide cytotoxicity tests, molecular docking studies
N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)acetamide
-
IC50: 0.012 mM
N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-3-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)propanamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(2-methylpropanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(3-methylbutanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(methylsulfonyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-methylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-phenylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propanoylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-[2-(methylsulfonyl)ethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydrofuran-3-yl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
N-[DL-[2-(hydroxyamino-carbonyl)methyl]-4-methylpentanoyl]-L-3-(tert-butyl)glycyl-L-alanine,2-aminoethylamide
-
-
N-[[(4R)-2,5-dioxoimidazolidin-4-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[[1-(hydroxycarbamoyl)cyclohexyl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[[5-(1-methylethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000019 mM
N-[[5-(1-methylpiperidin-4-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000057 mM
N-[[5-(4-acetylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000005 mM
N-[[5-(4-benzylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000014 mM
N-[[5-(4-ethynylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000062 mM
N-[[5-(4-methylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000058 mM
N1-benzyloxy-2(R)-benzyloxymethyl-N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-3(S)-(4-methoxyphenyl)-succinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(R)-(isobutyl)succinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(S)-(4-methoxyphenyl)succinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(S)-p-tolylsuccinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(S)-phenylsuccinamide
-
-
NaCl
-
dramatic inhibitory effect on the activity of TACE
peptide hydroxamate
-
-
-
peptidomimetic hydroxamate
-
-
-
PKF241-466
-
maximum inhibition at 10 mg/kg
pyridin-4-ylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
Ro32-7315
-
inhibitor specific for ADAM17, blocks shedding of CD30 antigen from cell membrane and a simultaneous release of soluble CD30
sulfonamide hydroxamate
-
-
tert-butyl (1S,2R)-4-{[imino(2-oxido-2-oxohydrazino)-methyl]amino}-2-methyl-1-[1,3-thiazol-2-ylaminocarbonyl]butylcarbamate
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-4-pentenoate
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-amino-3-methylpentanoate
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-azido-3-methylpentanoate
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-hydroxy-3-methylpentanoate
tert-butyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
tert-butyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
tert-butyl (5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)carbamate
-
IC50: 0.000013 mM
tert-butyl (5R,9R)-9-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate
-
-
tert-butyl 11-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1,3,5-trioxo-2,4,8-triazaspiro[5.5]undecane-8-carboxylate
-
-
tert-butyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
tert-butyl 3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoate
-
-
tert-butyl 4-(5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4,6-trioxohexahydropyrimidin-5-yl)piperazine-1-carboxylate
-
IC50: 0.00016 mM
tert-butyl 4-(5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)piperidine-1-carboxylate
-
IC50: 0.000047 mM
tert-butyl 4-(hydroxycarbamoyl)-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-1-carboxylate
-
-
tert-butyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
tert-butyl 4-([[4-(but-2-ynylamino)phenyl]sulfonyl]methyl)-4-[(hydroxyamino)-carbonyl]piperidine-1-carboxylate
-
-
tert-butyl 4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-6,8,10-trioxo-2,7,9-triazaspiro[4.5]decane-2-carboxylate
-
IC50: 0.000128 mM
tert-butyl 4-[([4-[but-2-ynyl(methyl)amino]phenyl]sulfonyl)methyl]-4-[(hydroxyamino)carbonyl]piperidine-1-carboxylate
-
-
tert-butyl(1S)-4-({(Z)-(methylsulfanyl)[(methylsulfonyl)-imino]methyl}amino)-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
tissue inhibitor of metalloproteinase-3
-
-
-
tissue inhibitor of metalloproteinases-3
-
natural inhibitor of ADAM17
-
TMI-2
-
complete inhibition at 50 nM
TNF-alpha proteinase inhibitor
-
0.00005 mM
-
tumor necrosis factor-alpha protease inhibitor
-
-
-
tumor necrosis factor-alpha-converting enzyme pro domain
-
inhibition of the tumor necrosis factor-alpha-converting enzyme by its isolated pro domain, IC50: 70 nM
-
[((3R,4S)-4-{[(benzyloxy)carbonyl]}-4-carboxy-3-methylbutyl)amino](imino)methanaminium nitrate (3R) 3-methyl L-arginine nitric acid salt
[N-hydroxy-1-(isopropylsulfonyl)-4-[(4-[(1-methylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)-methyl]piperidine-4-carboxamide
-
-
(1R,2S)-N2-hydroxy-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
(1R,2S)-N2-hydroxy-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(2R)-5-nitroguanyl-2-([(2R,3S)-2-(cyclohexylmethyl)-3-cyclopropyl-3-[formyl(hydroxy)amino]propanoyl]-amino)-N-(1,3-thiazol-2-yl)pentanamide
-
-
(2R)-5-nitroguanyl-2-([(2R,3S)-2-(cyclohexylmethyl)-3-cyclopropyl-3-[formyl(hydroxy)amino]propanoyl]-amino)-N-(1,3-thiazol-2-yl)pentanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(4-methylcyclohexyl)-methyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(4-methylcyclohexyl)-methyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(5-methyl-2-thienyl)methyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(5-methyl-2-thienyl)methyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutyl-4-methylpentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutyl-4-methylpentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutyl-4-methylpentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutyl-4-methylpentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-6,6,6-trifluoro-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-6,6,6-trifluoro-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-3-[formyl(hydroxy)amino]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-3-[formyl(hydroxy)amino]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-6,6,6-trifluoro-3-[formyl(hydroxy)amino]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-6,6,6-trifluoro-3-[formyl(hydroxy)amino]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-[(1S)-1-[formyl(hydroxy)amino]-2-phenylethyl]-4-methylpentanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-[(1S)-1-[formyl(hydroxy)amino]-2-phenylethyl]-4-methylpentanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[5-methyl-2-thienylmethyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[5-methyl-2-thienylmethyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
-
-
(2R,3S)-N-[(1S,2R)-4-nitroguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S,2R)-4-nitroguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-{(1R)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl}-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-{(1R)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl}-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2S)-2-amino-5-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-N-(1,3-thiazol-2-yl)pentanamide hydrochloride
-
-
(2S)-2-amino-5-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-N-(1,3-thiazol-2-yl)pentanamide hydrochloride
-
-
(2S)-2-[(tert-butoxycarbonyl)amino]-5-({(Z)-(methyl-sulfanyl)[(methylsulfonyl)imino]methyl}amino)pentanoic acid
-
-
(2S)-2-[(tert-butoxycarbonyl)amino]-5-({(Z)-(methyl-sulfanyl)[(methylsulfonyl)imino]methyl}amino)pentanoic acid
-
-
(2S,3R)-2-[(tert-butoxycarbonyl)amino]-5-{[imino(2-oxido-2-oxohydrazino)methyl]amino}-3-methylpentanoic acid (3R) Nalpha-boc-Ngamma-nitro-3-methyl L-arginine
-
-
(2S,3R)-2-[(tert-butoxycarbonyl)amino]-5-{[imino(2-oxido-2-oxohydrazino)methyl]amino}-3-methylpentanoic acid (3R) Nalpha-boc-Ngamma-nitro-3-methyl L-arginine
-
-
(2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-5-({(Z)-(methylsulfanyl)[(methylsulfonyl)imino]methyl}-amino)pentanoic acid
-
-
(2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-5-({(Z)-(methylsulfanyl)[(methylsulfonyl)imino]methyl}-amino)pentanoic acid
-
-
(2S,3R)-5-methanesulfonylguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
-
-
(2S,3R)-5-methanesulfonylguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
-
-
(2S,3R)-5-nitroguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
-
-
(2S,3R)-5-nitroguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
-
-
1,10-phenanthroline
-
-
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
synthesis of the specific inhibitor, overview
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
design and synthesis of the specific inhibitor, overview
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
synthesis of the specific inhibitor, overview
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
design and synthesis of the specific inhibitor, overview
4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide
-
IC50: 0.009 mM
4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide
-
IC50: 0.05 mM
BB 94
-
-
BB3103
-
-
-
benzyl (1S,2R)-4-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
-
-
benzyl (1S,2R)-4-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
-
-
BMS-561392
-
-
BMS-561392
-
TACE inhibitor also named DPC-333 is administered 15 min before ranitidine or its vehicle. Serum TNF-alpha concentration are measured 1 h afterwards. lipopolysaccharide/ranitidine treatment causes a significant increase in serum TNF-alpha concentration compared with lipopolysaccharide/vehicle treatment. Inhibitor does not affect serum TNF-alpha concentration after lipopolysaccharide/vehicle treatment. By contrast, it decreases serum TNF-alpha concentration after lipopolysaccharide/ranitidine treatment to the same level as lipopolysaccharide/vehicle treatment at both 1 h. In addition, TACE inhibitor decreases plasma active plasminogen activator inhibitor-1 concentration after lipopolysaccharide/ranitidine treatment to almost the same level as lipopolysaccharide/vehicle treatment
EDTA
-
-
EDTA
-
1 mM, treatment of cells dramatically inhibits shedding of shedding of FcalphaR, i.e. Fc receptor for immunoglobulin A
EndoH
-
full-length TACE is sensitive to EndoH, mature TACE is resistant
-
EndoH
-
full-length TACE is sensitive to EndoH, mature TACE is resistant
-
EndoH
-
full-length TACE is sensitive to EndoH, mature TACE is resistant
-
GM6001
-
broad-spectrum metalloproteinase inhibitor, treatment of cells dramatically inhibits shedding of shedding of FcalphaR, i.e. Fc receptor for immunoglobulin A
GM6001
-
poor inhibitive effectiveness on TACE
GW 3333
-
-
GW 3333
-
N-hydroxyformamide TACE inhibitor
GW280264X
-
blocks ADAM10 and ADAM17 activity similarly
GW9471
-
hydroxamic acid competitive inhibitor that totally blocks TACE activity
Hydroxamate
-
-
L-NG-(2-pyridylsulfonyl)arginine2-aminothiazole amide hydochloride
-
-
L-NG-(2-pyridylsulfonyl)arginine2-aminothiazole amide hydochloride
-
-
L-NG-nitroarginine 2-aminothiazole amide dihydrochloride
-
-
L-NG-nitroarginine 2-aminothiazole amide dihydrochloride
-
-
macrocyclic hydroxamic acid
-
-
macrocyclic hydroxamic acid
-
-
N(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-alanine amide
-
IC50: about 0.11 mM
N(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-alanine amide
-
IC50: about 0.7 mM
N-[2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
N-[2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
PF-548
selective inhibitor
PF-548
-
selective inhibitor
PKF242-484
-
-
PKF242-484
-
maximum inhibition at 10 mg/kg
TACE-pro domain
-
pro domain is an inhibitor of the catalytic domain
-
TAPI
-
hydroxamic acid-based broad-spectrum inhibitor of zinc metalloproteinases
TAPI
-
selective inhibitor
TAPI-1
-
-
TAPI-1
-
TAPI-1 inhibits 19% and 45% of enzyme activity at 0.0001 and 0.0001 mM, respectively
TAPI-1
-
TAPI-1 blocks the processing of RA175/SynCAM1, a member of the immunoglobulin family 4. Furthermore, TAPI-1 increases the number of synaptophysin and RA175/SynCAM1 colocalization on the dendrites of neurons
TAPI-2
-
hydroxamate-based inhibitor of matrix metalloproteases that has high activity against TACE
tert-butyl (1S,2R)-4-{[imino(2-oxido-2-oxohydrazino)-methyl]amino}-2-methyl-1-[1,3-thiazol-2-ylaminocarbonyl]butylcarbamate
-
-
tert-butyl (1S,2R)-4-{[imino(2-oxido-2-oxohydrazino)-methyl]amino}-2-methyl-1-[1,3-thiazol-2-ylaminocarbonyl]butylcarbamate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-4-pentenoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-4-pentenoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-amino-3-methylpentanoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-amino-3-methylpentanoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-azido-3-methylpentanoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-azido-3-methylpentanoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-hydroxy-3-methylpentanoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-hydroxy-3-methylpentanoate
-
-
tert-butyl(1S)-4-({(Z)-(methylsulfanyl)[(methylsulfonyl)-imino]methyl}amino)-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
-
-
tert-butyl(1S)-4-({(Z)-(methylsulfanyl)[(methylsulfonyl)-imino]methyl}amino)-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
-
-
TIMP-3
-
tissue inhibitor of metalloproteases-3, CAS: 147783-68-4, 171039-15-9, 13037-60-4
-
TIMP-3
-
85% inhibition at 10 nM
-
TIMP-3
-
presence of TIMP-3 inhibits shedding of lipoprotein-related protein I
-
TMI-1
-
-
TMI-1
complete inhibition at 0.01 mM
[((3R,4S)-4-{[(benzyloxy)carbonyl]}-4-carboxy-3-methylbutyl)amino](imino)methanaminium nitrate (3R) 3-methyl L-arginine nitric acid salt
-
-
[((3R,4S)-4-{[(benzyloxy)carbonyl]}-4-carboxy-3-methylbutyl)amino](imino)methanaminium nitrate (3R) 3-methyl L-arginine nitric acid salt
-
-
additional information
-
endothelial protein C receptor shedding is not influenced by DMSO, TIMP-1 or TIMP-2
-
additional information
secondary binding site (exosite) inhibitors provide a viable alternative to active site inhibitors, library screening and inhibitor design and synthesis, ADAM17 inhibition occurs via a non-zinc-binding mechanism, kinetic study, overview
-
additional information
-
the enzyme is not inhibited by 0.005 mM glutathione
-
additional information
-
not inhibited by FN-439
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0011
(1R,2R)-2-(3-phenoxylphenyl)-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
0.000008
(1R,2R)-2-trans-carboisopropoxyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
0.00014
(1R,2R)-2-trans-N-benzylaminocarbonyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
0.000011
(1R,2R)-2-[3-(3,4-dichlorobenzyloxy)phenyl]-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
0.005
(1R,2R)-N-hydroxy-2-[(4-methylpiperazin-1-yl)carbonyl]-2-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxamide
-
-
0.003
(1R,2R)-N1-benzyl-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
0.000009
(1R,2R)-N1-cyclohexyl-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
0.000011
(1R,2R)-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]-N1-phenylcyclopropane-1,2-dicarboxamide
-
-
0.0027
(1R,2R)-N2-hydroxy-N1,N1-dimethyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
0.0001
(1R,2R)-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
0.00000015
(1R,2S)-1-(3-fluoro-4-[[2-(1-methyl-1H-pyrazol-5-yl)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
0.00000076
(1R,2S)-1-(3-fluoro-4-[[2-(methylamino)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
0.00000021
(1R,2S)-1-[3-fluoro-4-[(2-morpholin-4-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
0.00000036
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxy-N1,N1-dimethylcyclopropane-1,2-dicarboxamide
-
0.00000014
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
0.00000014
(1R,2S)-1-[3-fluoro-4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
0.00000015
(1R,2S)-1-[3-fluoro-4-[(2-pyrrolidin-1-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
0.00036
(1R,2S)-1-[4-(benzyloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.00008
(1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.000001
(1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
0.000003
(1R,2S)-N2-hydroxy-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
0.00000063
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N1-(piperidin-4-ylmethyl)cyclopropane-1,2-dicarboxamide
-
0.00000018
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
0.000001
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
0.00000028
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
0.000014
(1R,2S)-N2-hydroxy-N1-methyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
0.00000038
(1S,2R)-2-[[(3R)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
0.00000054
(1S,2R)-2-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
0.0000003
(1S,2R)-N-hydroxy-2-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
0.00000025
(1S,2R)-N-hydroxy-2-[[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
0.000012
(1S,2R)-N-hydroxy-2-{4-[(2-imino-1,2-dihydroquinolin-4-yl)methoxy]benzyl}-2-(methoxycarbonyl)cyclopropanecarboximidic acid
-
-
0.000004
(1S,2S)-2-((S)-cyano(4-((2-phenylquinolin-4-yl)methoxy)phenyl)methyl)-N-hydroxycyclopropanecarboxamide
-
0.000071
(2R)-N-hydroxy-2-(7-methoxy-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl)-3-methylbutanamide
-
-
0.000028
(3S)-1-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]pyrrolidine-3-thiol
-
-
0.000001
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
-
0.000002
(5R)-5-(2',4'-difluorobiphenyl-4-yl)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000002
(5R)-5-(4'-chlorobiphenyl-4-yl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.00001
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[2'-(1-methyl-1H-tetrazol-5-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000018
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(trifluoromethyl)biphenyl-4-yl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000002
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000001
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000008
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(quinolin-6-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000031
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[3'-(2-methyl-1,3-thiazol-4-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000002
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(1H-pyrazol-3-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000006
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1,3-thiazol-2-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000002
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000003
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000002
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methyl-2H-indazol-6-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000005
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methylpyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000028
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(3-phenyl-1,2-oxazol-5-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000026
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(4-methyl-2,5-dioxoimidazolidin-4-yl)phenyl]imidazolidine-2,4-dione (non-preferred name)
-
pH and temperature not specified in the publication
0.0000012
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrazin-2-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000005
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-2-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000008
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000006
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000009
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrimidin-5-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000014
(5R)-5-[4-(2-aminopyridin-4-yl)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000005
(5R)-5-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000001
(5R)-5-[4-(5-chloro-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000008
(5S)-5-(4-fluorophenyl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000005
1-methylethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
0.00019
2-(3-benzyloxyphenyl)-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
0.0007
2-[3-(2-methylquinolin-4-yl)methoxylphenyl]-2-trans-carboxamidocyclopropane hydroxyamic acid
-
-
0.000008
2-[3-(2-methylquinolin-4-yl)methoxyphenyl]-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
0.000002
2-[[4-(but-2-yn-1-ylamino)phenyl]sulfonyl]ethanethiol
-
-
0.000008
2-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]ethanethiol
-
-
0.00001
2-[[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl](methyl)amino]-N-hydroxyacetamide
-
-
0.000017
3-[[4-(but-2-yn-1-ylamino)phenyl]sulfonyl]cyclohexanethiol
-
-
0.0000045
3-[[4-(but-2-yn-1-ylamino)phenyl]sulfonyl]propane-1-thiol
-
-
0.00003
3-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]cyclohexanethiol
-
-
0.00005
3-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]cyclopentanethiol
-
-
0.00001
3-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]propane-1-thiol
-
-
0.000003
4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxamide
-
pH and temperature not specified in the publication
0.000006
5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-phenylimidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000029
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(2-phenoxyphenyl)imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000027
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(3-phenoxyphenyl)imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000008
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-oxopyrrolidin-1-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000006
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(morpholin-4-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000007
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yloxy)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000006
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrrolidin-1-ylcarbonyl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000003
5-[4-(cyclopentyloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000008
5-[4-(isoquinolin-7-yloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000016
ethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
0.000381
ethyl (1R,2S)-1-[3-bromo-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
0.000158
ethyl (1R,2S)-1-[3-chloro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
0.000005
ethyl (1R,2S)-1-[3-fluoro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
0.000002
ethyl (1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
0.0031
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-phenoxybenzyl)cyclopropanecarboxylate
-
-
0.000018
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(2-methylpropyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
0.000003
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(trifluoromethyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
0.000006
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
0.000037
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylpyridin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
0.000012
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
0.000022
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
0.00005
methyl (1R,2R)-1-[3-(2-[3-[(1Z)-buta-1,3-dien-1-yl]phenyl]ethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.0012
methyl (1R,2R)-1-[3-(benzyloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.0016
methyl (1R,2R)-1-[3-(but-2-yn-1-yloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.0009
methyl (1R,2R)-1-[3-(cyclohexylmethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.00005
methyl (1R,2R)-1-[3-[(4-chlorobenzyl)oxy]phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.003
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-methoxyphenyl)cyclopropanecarboxylate
-
-
0.00007
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[3-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
0.000018
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[4-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
0.00024
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
0.00006
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-naphthalen-2-ylethoxy)phenyl]cyclopropanecarboxylate
-
-
0.00029
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-phenylethoxy)phenyl]cyclopropanecarboxylate
-
-
0.00014
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(4-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
0.003
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-ylmethoxy)phenyl]cyclopropanecarboxylate
-
-
0.00007
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-yloxy)phenyl]cyclopropanecarboxylate
-
-
0.00011
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(3-methoxybenzyl)oxy]phenyl]cyclopropanecarboxylate
-
-
0.0008
methyl (1R,2S)-1-[4-(benzyloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.00042
methyl (1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.026
methyl (1R,2S)-1-[4-(cyclohexylmethoxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.00026
methyl (1R,2S)-1-[4-[(2-chlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.00013
methyl (1R,2S)-1-[4-[(3,4-dichlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.1
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-1-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
0.1
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-2-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
0.000013
methyl (5R)-5-{7-[(3,5-diethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate
-
-
0.00001
methyl (5R)-5-{7-[(3,5-dimethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate
-
-
0.000009
methyl 4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxylate
-
pH and temperature not specified in the publication
0.0031
N-hydroxy-2(R)-(6-methoxy-1,1-dioxo-3,4-dihydro-1H-1-benzo[1,2,4]thiadiazin-2-yl)propionamide
-
-
0.000484
N-hydroxy-2(R)-[2,3,4,5-tetrahydrobenzo[1,2,5-f]-thiadiazepine-1,1-dioxide]propanamide
-
-
0.000544
N-hydroxy-2(R)-[7-(2,6-methylpyridyl-4-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propanamide
-
-
0.001
N-hydroxy-2(R)-[7-(2-trifluromethylphenyl)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide
-
value above
0.000153
N-hydroxy-2(R)-[7-(3,5-dichlorobenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.000051
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
-
-
0.000242
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide
-
-
0.000081
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.000005
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine 1,1-dioxide]-6-N-(methanesulfonyl)hexylamide
-
-
0.00001
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
-
-
0.000177
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide
-
-
0.000017
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide
-
-
0.000031
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-aminohexylamidetrifluoroacetic acid salt
-
-
0.000077
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-N-[(1,1-dimethylethoxy)carbonyl]hexylamide
-
-
0.000027
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.000229
N-hydroxy-2(R)-[7-(3,5-dimethylbenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.000129
N-hydroxy-2(R)-[7-(3-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.00029
N-hydroxy-2(R)-[7-(4,5-dimethylthiazolyl-2-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
-
-
0.000621
N-hydroxy-2(R)-[7-(4-methoxyphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.000011
N-hydroxy-2(R)-[7-(4-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.001
N-hydroxy-2(R)-[7-(4-phenylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
value above
0.000758
N-hydroxy-2(R)-[7-(4-trifluoromethylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.001
N-hydroxy-2(R)-[7-(N-3,5-dimethylbenzoylamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propylamide
-
value above
0.000177
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide
-
-
0.000705
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.000089
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide
-
-
0.000391
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.000274
N-hydroxy-2(R)-[7-methoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.000056
N-hydroxy-2(R)-[7-N-(3,5-dimethoxymethyleneamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide
-
-
0.000734
N-hydroxy-2(R)-[7-phenoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
0.001
N-hydroxy-2(R)-[7-phenyl-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide
-
value above
0.001
N-hydroxy-2-[2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide
-
-
0.001
N-hydroxy-2-[7-methoxy-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide
-
-
0.00008
N-[(4S,5S,7R)-2-[7-(1-benzylpiperidin-4-yl)]methylcarbamoyl-5-hydroxy-2-methyloct-4-yl]-N'-[(R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]isophthalamide
-
-
additional information
additional information
inhibition kinetics, overview
-
0.000003
(1R,2S)-N2-hydroxy-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
0.000003
(1R,2S)-N2-hydroxy-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0000026
(3R,4R)-4-([[4-(1,3-dihydrofuro[3,4-b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.000001
(3R,4R)-4-([[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.0000013
(3R,4R)-4-([[4-(2,3-dihydrofuro[2,3-b]quinolin-4-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.0000012
(3R,4R)-4-[([4-[(2,3-dimethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.0000013
(3R,4R)-4-[([4-[(2-cyclopropylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.0000017
(3R,4R)-4-[([4-[(2-ethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.0000078
(3R,4R)-4-[([4-[(3-ethyl-2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.0000012
(3R,4R)-4-[[(4-[[2-(dimethylamino)quinolin-4-yl]methyl]phenyl)carbonyl]amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.000001
(3R,4R)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.0000016
(3R,4R)-N-hydroxy-4-[([4-[(2-morpholin-4-ylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.0000015
(3R,4R)-N-hydroxy-4-[([4-[(3-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.000001
(3R,4R)-N-hydroxy-4-[[(4-[[2-(1-methylethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
IC50 below 0.000001 mM
0.0000022
(3R,4R)-N-hydroxy-4-[[(4-[[2-(trifluoromethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.000001
(3R,4S)-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
Sus scrofa
-
IC50 below 0.000001 mM
0.000001 - 0.0000023
(3R,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
0.0000023
(3S)-4-[[4-(but-2-ynylamino)phenyl]sulfonyl]-N-hydroxy-2,2-dimethylthio-morpholine-3-carboxamide
Homo sapiens
-
-
0.000024
(3S,4R)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-3-carboxamide
Sus scrofa
-
-
0.0000015
(3S,4S)-1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000016
(3S,4S)-1-(2,2-dimethylpropyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000011
(3S,4S)-1-(butylsulfonyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.000002
(3S,4S)-1-(furan-2-ylmethyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000013
(3S,4S)-1-acetyl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-1-but-2-yn-1-yl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-1-cyclobutyl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.000002
(3S,4S)-1-tert-butyl-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
Sus scrofa
-
-
0.000002
(3S,4S)-1-[2-(dimethylamino)ethyl]-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-3-[([4-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-3-[([4-[(2-ethyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.000002
(3S,4S)-3-[([4-[(2-ethylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.0000028
(3S,4S)-3-[([4-[(2-tert-butylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.0000004
(3S,4S)-N-hydroxy-1-(1-methylethyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000015
(3S,4S)-N-hydroxy-1-(2-methylprop-2-en-1-yl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000021
(3S,4S)-N-hydroxy-1-(2-methylpropanoyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000011
(3S,4S)-N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000016
(3S,4S)-N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000016
(3S,4S)-N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000025
(3S,4S)-N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000016
(3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.000006
(3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-N-hydroxy-3-[([4-[(2-methylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
IC50 below 0.000001 mM
0.0000021
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.0000032
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.0000017
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.0000015
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000022
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000016
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-phenylpyrrolidine-3-carboxamide
Sus scrofa
-
-
0.00000094
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-prop-2-en-1-ylpyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000063
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000043
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
Sus scrofa
-
-
0.000001
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000035
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0000018
(3S,4S)-N-hydroxy-4-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]pyrrolidine-3-carboxamide
Sus scrofa
-
-
0.0042
(5R)-4-(2-((1R,3R)-adamantan-1-yl)ethyl)-5-(4-hydroxybenzyl)-1-((2R)-1-(2-(((R)-6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl)-methyl)pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.00023
(5R,6R)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4-dioxo-1,3-diazaspiro[4.4]nonane-6-carboxamide
Sus scrofa
-
-
0.000064
(5R,6S)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4-dioxo-1,3-diazaspiro[4.4]nonane-6-carboxamide
Sus scrofa
-
-
0.000001
(5R,7S,8R)-N-hydroxy-8-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-oxaspiro[4.4]nonane-7-carboxamide
Sus scrofa
-
-
0.015
(5S)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)-methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)-4-(2-phenylbutyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.000011
(5S,6R)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4-dioxo-1,3-diazaspiro[4.5]decane-6-carboxamide
Sus scrofa
-
-
0.000001
(5S,6S)-N-hydroxy-5-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-2,3,5,6-tetrahydro-4aH-cyclopenta[b][1,4]dioxine-6-carboxamide
Sus scrofa
-
-
0.000001
(5S,7S,8R)-N-hydroxy-8-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-oxaspiro[4.4]nonane-7-carboxamide
Sus scrofa
-
-
0.000001
(7S,8R)-N-hydroxy-8-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1,4-dioxaspiro[4.4]nonane-7-carboxamide
Sus scrofa
-
-
0.0054
(R)-4-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0079
(R)-4-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(naphthalen-2-ylmethyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0057
(R)-4-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-5-(naphthalen-2-ylmethyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.015
(R)-4-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)-5-(4-hydroxybenzyl)-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0054
(S)-1((R)-1((S)-2-(((S)-6-benzyl-2,3-dioxopiperazin-1-yl)methyl)-pyrrolidin-1-yl)-3-cyclohexylpropan-2-yl)-5-(4-hydroxybenzyl)-4-phenethylpiperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.01
(S)-4-((3S,5S,7S)-adamantan-1 -ylmethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.01
(S)-4-((4-(tert-butyl)cyclohexyl)methyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0059
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.01
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(naphthalen-2-ylmethyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0084
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-5-(naphthalen-2-ylmethyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0081
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-5-(4-hydroxybenzyl)-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0065
(S)-4-(2-((3S,5S,7S)-adamantan-1-yl)ethyl)-5-butyl-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0057
(S)-4-(2-(adamantan-1-yl)ethyl)-5-butyl-1-((S)-1-(4-hydroxyphenyl)-3-((S)-2-(((R)-6-(naphthalen-2-ylmethyl)-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.011
(S)-4-(2-(adamantan-1yl)ethyl)-1-((S)-1-((S)-2-(((S)-6-benzyl-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-phenylpropan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.094
(S)-4-(cyclobutylmethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.029
(S)-4-(cyclohexylmethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.035
(S)-4-(cyclopentylmethyl)-1-((S)-1-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl)-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0085
(S)-5-benzyl-1-((R)-1-((S)-2-(((S)-6-benzyl-2,3-dioxopiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-cyclohexylpropan-2-yl)-4-phenethylpiperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0043
(S)-5-benzyl-1-((R)-1-cyclohexyl-3-((S)-2-(((S)-2,3-dioxo-6-propylpiperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-4-phenethylpiperazine-2,3-dione
Homo sapiens
at pH 7.5 and 37°C
0.0000011
1-(1,3-benzoxazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
-
0.000001
1-(1H-benzimidazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
IC50 above 0.000001 mM
0.0000015
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens
-
-
0.0000023
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000016
1-(2,2-dimethylpropyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens
-
-
0.0000011
1-(butylsulfonyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens
-
-
0.000001
1-but-2-yn-1-yl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens
-
-
0.0000012
1-ethylpropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
-
0.0000014
1-methyl-2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
-
0.0000015
1-methylethyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
Sus scrofa
-
-
0.0000015
1-methylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
-
0.0000015
1-[(4-acetylpiperazin-1-yl)sulfonyl]-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
-
0.05 - 0.06
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
0.051 - 0.058
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
0.0073
1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]-1,3,5-triazinane-2,4,6-trione
Sus scrofa
-
IC50: 0.0073 mM
0.00015
13-[(4R)-2,5-dioxoimidazolidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]tridecanamide
Sus scrofa
-
-
0.000003
2,6-anhydro-3,4,5-trideoxy-1-(hydroxyamino)-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-D-threo-hexose
Sus scrofa
-
-
0.00003
2-(6-methyl-2-oxo-2H-chromen-3-ylmethyl)-pent-4-enoic acid hydroxyamide
Homo sapiens
-
at 25°C
0.000005
2-benzyl-N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
Homo sapiens
-
at 25°C
0.0000022
2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
-
0.0074
2-[(5R,6R)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]acetamide
Sus scrofa
-
-
0.000017
2-[(5R,6S)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]acetamide
Sus scrofa
-
-
0.1
2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]acetamide
0.00084
3-(6-bromo-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
Homo sapiens
-
at 25°C
0.00055
3-(6-chloro-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
Homo sapiens
-
at 25°C
0.0124
3-(6-tert-butyl-2-oxo-2H-chromen-3-yl)-N-hydroxypropanamide
Homo sapiens
-
at 25°C
0.0000026
3-([[4-(1,3-dihydrofuro[3,4-b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.000001
3-([[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.0000013
3-([[4-(2,3-dihydrofuro[2,3-b]quinolin-4-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.0000012
3-[([4-[(2,3-dimethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.0000013
3-[([4-[(2-cyclopropylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.0000017
3-[([4-[(2-ethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.0000078
3-[([4-[(3-ethyl-2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.0000032
3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoic acid
Homo sapiens
-
-
0.0000012
3-[[(4-[[2-(dimethylamino)quinolin-4-yl]methyl]phenyl)carbonyl]amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.031 - 0.045
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
0.054 - 0.056
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
0.05 - 0.059
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
0.00536 - 0.057
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
0.0000025
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-benzoyl)-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens
-
-
0.0000035
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-butyryl)-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens
-
-
0.000002
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(propane-2-sulfonyl)-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens
-
-
0.0000023
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-isobutyryl-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens
-
-
0.0000064
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-pyridin-4-ylmethyl-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens
-
-
0.000001
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-1,4-dicarboxylic acid 1-diethylamide 4-hydroxyamide
Homo sapiens
-
IC50 below 0.000001 mM
0.000064
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens
-
-
0.017 - 0.032
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
0.051 - 0.056
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
0.034 - 0.042
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
0.00432 - 0.09
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
0.0000018
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-(dimethylsulfamoyl)-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
-
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dichlorothiophen-3-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
IC50 below 0.000001 mM
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dimethyl-1,3-thiazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
IC50 below 0.000001 mM
0.0000017
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)carbonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
-
0.0000016
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)methyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
-
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
IC50 below 0.000001 mM
0.0000022
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
-
0.000007
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(5-chlorothiophen-2-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens
-
-
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(morpholin-4-ylsulfonyl)piperidine-4-carboxamide
Homo sapiens
-
-
0.0000012
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(piperidin-1-ylsulfonyl)piperidine-4-carboxamide
Homo sapiens
-
-
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(pyrrolidin-1-ylsulfonyl)piperidine-4-carboxamide
Homo sapiens
-
-
0.00000133
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-2-ylpiperidine-4-carboxamide
Homo sapiens
-
-
0.0000056
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-4-ylpiperidine-4-carboxamide
Homo sapiens
-
-
0.000003
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[(2-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000014
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000015
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000138
4-[(2-methylquinolin-4-yl)methoxy]-N-(1,3,5-trioxo-2,4-diazaspiro[5.5]undec-7-yl)benzamide
0.1
4-[(2-methylquinolin-4-yl)methoxy]-N-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)benzamide
0.000044
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-2-oxa-7,9-diazaspiro[4.5]dec-4-yl)benzamide
0.000024
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-7,9-diazaspiro[4.5]dec-1-yl)benzamide
0.000031
4-[(2-methylquinolin-4-yl)methoxy]-N-([2,4,6-trioxo-5-[1-(tetrahydro-2H-pyran-2-yl)piperidin-4-yl]hexahydropyrimidin-5-yl]methyl)benzamide
Sus scrofa
-
-
0.000031
4-[(2-methylquinolin-4-yl)methoxy]-N-([2,4,6-trioxo-5-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]hexahydropyrimidin-5-yl]methyl)benzamide
Sus scrofa
-
IC50: 0.000031 mM
0.00001
4-[(2-methylquinolin-4-yl)methoxy]-N-([2,4,6-trioxo-5-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]hexahydropyrimidin-5-yl]methyl)benzamide
Sus scrofa
-
IC50: 0.00001 mM
0.000029
4-[(2-methylquinolin-4-yl)methoxy]-N-([5-[1-(methylsulfonyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)benzamide
Sus scrofa
-
IC50: 0.000029 mM
0.000002
4-[(2-methylquinolin-4-yl)methoxy]-N-([5-[4-(methylsulfonyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)benzamide
Sus scrofa
-
IC50: 0.000002 mM
0.000018
4-[(2-methylquinolin-4-yl)methoxy]-N-[(2,4,6-trioxo-5-phenylhexahydropyrimidin-5-yl)methyl]benzamide
Sus scrofa
-
-
0.000055
4-[(2-methylquinolin-4-yl)methoxy]-N-[(2,4,6-trioxo-5-piperidin-4-ylhexahydropyrimidin-5-yl)methyl]benzamide
0.00236
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-yl)methyl]benzamide
0.000026
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]benzamide
0.000036
4-[(2-methylquinolin-4-yl)methoxy]-N-[2-(methylsulfonyl)-6,8,10-trioxo-2,7,9-triazaspiro[4.5]dec-4-yl]benzamide
Sus scrofa
-
IC50: 0.000036 mM
0.000029
4-[(2-methylquinolin-4-yl)methoxy]-N-[6,8,10-trioxo-2-(pyridin-3-ylcarbonyl)-2,7,9-triazaspiro[4.5]dec-4-yl]benzamide
Sus scrofa
-
IC50: 0.000029 mM
0.000014
4-[(2-methylquinolin-4-yl)methoxy]-N-[[2,4,6-trioxo-5-(4-phenylpiperazin-1-yl)hexahydropyrimidin-5-yl]methyl]benzamide
Sus scrofa
-
-
0.000027
4-[([4-[(1,1-dimethylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)methyl]-N-hydroxy-1-(isopropylsulfonyl)piperidine-4-carboxamide
Homo sapiens
-
-
0.0000028
4-[2-(hydroxyamino)-2-oxoethyl]-N,N-dimethyl-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-1-carboxamide
Homo sapiens
-
-
0.00001
4-[4-(4-hydroxy-but-2-ynylamino)-benzenesulfonylmethyl]-4-hydroxycarbamoyl-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
-
0.009 - 0.05
4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide
0.00062
5-(4-acetylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.00062 mM
0.000195
5-(4-benzylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.000195 mM
0.000081
5-(4-hexylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.000081 mM
0.056 - 0.06
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
0.062
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamanylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.061 - 0.095
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
0.000091
5-(4-methylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.000091 mM
0.049
5-methyl-5-(2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]ethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
0.0008
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-3-oxopropyl)pyrimidine-2,4,6(1H,3H,5H)-trione
0.011
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.011 mM
0.1
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]propyl)pyrimidine-2,4,6(1H,3H,5H)-trione
0.011
5-methyl-5-[(2E)-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]prop-2-en-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
-
0.0022
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]pyrimidine-2,4,6(1H,3H,5H)-trione
0.0013
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenoxy]pyrimidine-2,4,6(1H,3H,5H)-trione
0.0037
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]dihydropyrimidine-2,4(1H,3H)-dione
Sus scrofa
-
IC50: 0.0037 mM
0.00103
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
0.000096
5-[4-(1-methylethyl)piperazin-1-yl]-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.000096 mM
0.00054
5-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.00054 mM
0.00016
5-[4-(2,2-dimethylpropyl)piperazin-1-yl]-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.00016 mM
0.000535
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-(pyridin-3-ylcarbonyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.000535 mM
0.0011
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-piperazin-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.0011 mM
0.000855
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-piperidin-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.000855 mM
0.000084
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(2-phenylethyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.000084 mM
0.00011
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(3-phenylpropyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.00011 mM
0.0028
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(4-nitrophenyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.0028 mM
0.000275
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.000275 mM
1
7-(1-methyl-2,5-dioxoimidazolidin-4-yl)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
Sus scrofa
-
-
0.00021
7-(2,5-dioxoimidazolidin-4-yl)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
Sus scrofa
-
-
1
7-(3-methyl-2,5-dioxoimidazolidin-4-yl)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
Sus scrofa
-
-
0.00017
7-[(4R)-2,5-dioxoimidazolidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
Sus scrofa
-
-
0.0037
7-[(4S)-2,5-dioxoimidazolidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
Sus scrofa
-
-
0.0000028
cyclohexyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
-
0.000001
cyclohexylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
IC50 above 0.000001 mM
0.0000013
cyclopentyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
-
0.0000016
cyclopropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
-
0.000028
gelastatin hydroxamate
Homo sapiens
-
at 25°C
0.000317
GM6001
Homo sapiens
-
in 25 mM Tris-HCl buffer, pH 9, 0.0025 mM ZnCl2 and 0.005% (v/v) Brij-35, at 37°C
0.000014
INCB3619
Homo sapiens
at pH 7.5 and 37°C
0.00006 - 0.000065
JMV 390
0.000001
methyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
Sus scrofa
-
-
0.0000033
methyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
Sus scrofa
-
-
0.0011
methyl (5R)-5-{7-[(3,5-diethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0009
methyl (5R)-5-{7-[(3,5-dimethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0000033
methyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
Homo sapiens
-
-
0.0047
methyl 4-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,5-dioxoimidazolidine-4-carboxylate
Sus scrofa
-
IC50: 0.0047 mM
0.11 - 0.7
N(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-alanine amide
0.000055
N-(2-acetyl-6,8,10-trioxo-2,7,9-triazaspiro[4.5]dec-4-yl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000055 mM
0.000055
N-(8-acetyl-1,3,5-trioxo-2,4,8-triazaspiro[5.5]undec-11-yl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000052
N-([5-[1-(1-methylethyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
0.000013
N-([5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000013 mM
0.000007
N-([5-[4-(1-methylethyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
0.000029
N-([5-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000029 mM
0.000062
N-([5-[4-(5-amino-8-carbamimidamido-4-oxooctyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.0000016
N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens
-
-
0.0000025
N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens
-
-
0.0029
N-hydroxy-2(R)-[7-(2,6-methylpyridyl-4-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.00094
N-hydroxy-2(R)-[7-(3,5-dichlorobenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0082
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0062
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0045
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0019
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine 1,1-dioxide]-6-N-(methanesulfonyl)hexylamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.004
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0072
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0054
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.00077
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.00047
N-hydroxy-2(R)-[7-(3-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0245
N-hydroxy-2(R)-[7-(4,5-dimethylthiazolyl-2-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0012
N-hydroxy-2(R)-[7-(4-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.00084
N-hydroxy-2(R)-[7-(4-trifluoromethylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.00035
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.0095
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide
Sus scrofa
-
human peripheral blood mononuclear cell assay (PBMC)
0.000036
N-hydroxy-2-((6-methoxy-2H-chromen-3-yl)methyl)propanamide
Homo sapiens
-
at 25°C
0.000175
N-hydroxy-2-(2-oxo-2H-chromen-3-yl)acetamide
Homo sapiens
-
in 25 mM Tris-HCl buffer, pH 9.0, 0.0025 mM ZnCl2 and 0.005% (v/v) Brij-35, at 37°C
0.000003
N-hydroxy-2-methyl-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
Homo sapiens
-
at 25°C
0.00015
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
Homo sapiens
-
at 25°C
0.00011
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)propanamide
Homo sapiens
-
at 25°C
0.00006
N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)propanamide
Homo sapiens
-
at 25°C
0.0000016
N-hydroxy-3-[([4-[(2-morpholin-4-ylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.0000015
N-hydroxy-3-[([4-[(3-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.0000022
N-hydroxy-3-[[(4-[[2-(trifluoromethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-2-carboxamide
Homo sapiens
-
-
0.0000063
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens
-
-
0.0000043
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
Homo sapiens
-
-
0.000001
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
Sus scrofa
-
-
0.000001
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
-
0.000002
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
Homo sapiens
-
-
0.0000035
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens
-
-
0.0000019
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-(methylsulfonyl)piperidine-4-carboxamide
Homo sapiens
-
-
0.000011
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-propylpiperidine-4-carboxamide
Homo sapiens
-
-
0.0000049
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.0000023
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]tetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
-
0.0000018
N-[(1R,2S)-2-(hydroxycarbamoyl)-4-oxocyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.0002
N-[(1R,2S)-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.00000063
N-[(1R,2S)-4,4-difluoro-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000001
N-[(1R,2S)-4-aziridin-1-yl-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50 below 0.000001 mM
0.0000046
N-[(1R,2S)-4-hydroxy-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000001
N-[(1S,2R)-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000029
N-[(4-methyl-2,5-dioxoimidazolidin-4-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000018
N-[(5-benzyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000018 mM
0.000016
N-[(5-ethyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
0.0009
N-[(5R,6R)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000024
N-[(5R,6R)-2,4-dioxo-1,3-diazaspiro[4.5]dec-6-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.0055
N-[(5R,6S)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000025
N-[(5R,9R)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000024
N-[(5R,9R)-7-(2-methylpropanoyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.0000023
N-[1-(1,1-dimethylprop-2-yn-1-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000021
N-[1-(2,2-dimethylpropanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000026
N-[1-(2,2-dimethylpropyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.000028
N-[1-(2,5-dioxoimidazolidin-4-yl)ethyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.0000026
N-[1-(2-fluoroethyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000019
N-[1-(3,3-dimethylbutanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000012
N-[1-(4,5-dihydro-1,3-thiazol-2-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000019
N-[1-acetyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000022
N-[1-ethyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000037
N-[1-tert-butyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000014
N-[1-[2-(ethylsulfonyl)ethyl]-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000077
N-[1-[2-(hydroxyamino)-2-oxoethyl]cyclohexyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.000097
N-[1-[2-(hydroxyamino)-2-oxoethyl]cyclohexyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
Sus scrofa
-
-
0.000111
N-[2-(2,2-dimethylpropanoyl)-6,8,10-trioxo-2,7,9-triazaspiro[4.5]dec-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000111 mM
0.000001
N-[2-(hydroxycarbamoyl)cyclobutyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.0000018
N-[2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
0.012
N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)acetamide
Sus scrofa
-
IC50: 0.012 mM
0.012
N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-3-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)propanamide
Sus scrofa
-
-
0.0000012
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(2-methylpropanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000022
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(3-methylbutanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.000001
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(methylsulfonyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000031
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-methylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000019
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-phenylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000027
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propanoylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.000002
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000012
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-[2-(methylsulfonyl)ethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.0000014
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.000097
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
Homo sapiens
-
-
0.000002
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydrofuran-3-yl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
Sus scrofa
-
-
0.000098
N-[[(4R)-2,5-dioxoimidazolidin-4-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.0000086
N-[[1-(hydroxycarbamoyl)cyclohexyl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens
-
-
0.000019
N-[[5-(1-methylethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
0.000057
N-[[5-(1-methylpiperidin-4-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
0.000005
N-[[5-(4-acetylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
0.000014
N-[[5-(4-benzylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000014 mM
0.000062
N-[[5-(4-ethynylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000062 mM
0.000058
N-[[5-(4-methylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
0.000002
pyridin-4-ylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
-
0.000041 - 0.000043
TAPI-2
0.000001
tert-butyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
Sus scrofa
-
-
0.0000013
tert-butyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
Sus scrofa
-
-
0.000013
tert-butyl (5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)carbamate
0.000013
tert-butyl (5R,9R)-9-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate
Sus scrofa
-
-
0.000128
tert-butyl 11-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1,3,5-trioxo-2,4,8-triazaspiro[5.5]undecane-8-carboxylate
Sus scrofa
-
-
0.0000013
tert-butyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
Homo sapiens
-
-
0.0000019
tert-butyl 3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoate
Homo sapiens
-
-
0.00016
tert-butyl 4-(5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4,6-trioxohexahydropyrimidin-5-yl)piperazine-1-carboxylate
Sus scrofa
-
IC50: 0.00016 mM
0.000047
tert-butyl 4-(5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)piperidine-1-carboxylate
0.0000024
tert-butyl 4-(hydroxycarbamoyl)-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-1-carboxylate
Homo sapiens
-
-
0.000001
tert-butyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens
-
IC50 above 0.000001 mM
0.0000016
tert-butyl 4-([[4-(but-2-ynylamino)phenyl]sulfonyl]methyl)-4-[(hydroxyamino)-carbonyl]piperidine-1-carboxylate
Homo sapiens
-
-
0.000128
tert-butyl 4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-6,8,10-trioxo-2,7,9-triazaspiro[4.5]decane-2-carboxylate
Sus scrofa
-
IC50: 0.000128 mM
0.0000033
tert-butyl 4-[([4-[but-2-ynyl(methyl)amino]phenyl]sulfonyl)methyl]-4 [(hydroxyamino)carbonyl]piperidine-1-carboxylate
Homo sapiens
-
-
0.000008
TMI-1
Homo sapiens
-
-
0.00007
tumor necrosis factor-alpha-converting enzyme pro domain
Homo sapiens
-
inhibition of the tumor necrosis factor-alpha-converting enzyme by its isolated pro domain, IC50: 70 nM
-
0.000004
[N-hydroxy-1-(isopropylsulfonyl)-4-[(4-[(1-methylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)-methyl]piperidine-4-carboxamide
Homo sapiens
-
-
0.000001
(3R,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
Sus scrofa
-
-
0.0000023
(3R,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
Sus scrofa
-
-
0.05
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.054
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.059
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.06
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.051
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.058
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.1
2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]acetamide
Sus scrofa
-
IC50 above 0.1 mM
0.1
2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]acetamide
Sus scrofa
-
IC50: above 0.1 mM
0.031
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.039
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.04
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.045
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.054
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.056
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.05
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.053
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.058
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.059
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.00536
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.054
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.057
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.017
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.018
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.032
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.051
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.056
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.034
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.035
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.038
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.042
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.00432
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.066
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.09
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.000138
4-[(2-methylquinolin-4-yl)methoxy]-N-(1,3,5-trioxo-2,4-diazaspiro[5.5]undec-7-yl)benzamide
Sus scrofa
-
-
0.000138
4-[(2-methylquinolin-4-yl)methoxy]-N-(1,3,5-trioxo-2,4-diazaspiro[5.5]undec-7-yl)benzamide
Sus scrofa
-
IC50: 0.000138 mM
0.1
4-[(2-methylquinolin-4-yl)methoxy]-N-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)benzamide
Sus scrofa
-
IC50 above 0.1 mM
0.1
4-[(2-methylquinolin-4-yl)methoxy]-N-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)benzamide
Sus scrofa
-
IC50: above 0.1 mM
0.000044
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-2-oxa-7,9-diazaspiro[4.5]dec-4-yl)benzamide
Sus scrofa
-
-
0.000044
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-2-oxa-7,9-diazaspiro[4.5]dec-4-yl)benzamide
Sus scrofa
-
IC50: 0.000044 mM
0.000024
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-7,9-diazaspiro[4.5]dec-1-yl)benzamide
Sus scrofa
-
-
0.000024
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-7,9-diazaspiro[4.5]dec-1-yl)benzamide
Sus scrofa
-
IC50: 0.000024 mM
0.000055
4-[(2-methylquinolin-4-yl)methoxy]-N-[(2,4,6-trioxo-5-piperidin-4-ylhexahydropyrimidin-5-yl)methyl]benzamide
Sus scrofa
-
-
0.000055
4-[(2-methylquinolin-4-yl)methoxy]-N-[(2,4,6-trioxo-5-piperidin-4-ylhexahydropyrimidin-5-yl)methyl]benzamide
Sus scrofa
-
IC50: 0.000055 mM
0.00236
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-yl)methyl]benzamide
Sus scrofa
-
-
0.00236
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-yl)methyl]benzamide
Sus scrofa
-
IC50: 0.00236 mM
0.000026
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]benzamide
Sus scrofa
-
-
0.000026
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]benzamide
Sus scrofa
-
IC50: 0.000026 mM
0.009
4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide
Homo sapiens
-
IC50: 0.009 mM
0.05
4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide
Mus musculus
-
IC50: 0.05 mM
0.056
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.06
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.061
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.095
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
Homo sapiens
pH 7.5, 22°C
0.049
5-methyl-5-(2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]ethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
-
0.049
5-methyl-5-(2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]ethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.049 mM
0.0008
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-3-oxopropyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
-
0.0008
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-3-oxopropyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.0008 mM
0.1
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]propyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50 above 0.1 mM
0.1
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]propyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: above 0.1 mM
0.0022
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
-
0.0022
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.0022 mM
0.0013
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenoxy]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
-
0.0013
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenoxy]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.0013 mM
0.00103
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
-
0.00103
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
Sus scrofa
-
IC50: 0.00103 mM
0.00006
JMV 390
Homo sapiens
-
mutant enzyme V353G
0.000065
JMV 390
Homo sapiens
-
wild type enzyme
0.11
N(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-alanine amide
Homo sapiens
-
IC50: about 0.11 mM
0.7
N(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-alanine amide
Mus musculus
-
IC50: about 0.7 mM
0.000052
N-([5-[1-(1-methylethyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000052
N-([5-[1-(1-methylethyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000052 mM
0.000007
N-([5-[4-(1-methylethyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000007
N-([5-[4-(1-methylethyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000007 mM
0.000016
N-[(5-ethyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000016
N-[(5-ethyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000016 mM
0.0000018
N-[2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
Homo sapiens
-
-
0.0000018
N-[2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
Sus scrofa
-
-
0.000019
N-[[5-(1-methylethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000019
N-[[5-(1-methylethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000019 mM
0.000057
N-[[5-(1-methylpiperidin-4-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000057
N-[[5-(1-methylpiperidin-4-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000057 mM
0.000005
N-[[5-(4-acetylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000005
N-[[5-(4-acetylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000005 mM
0.000058
N-[[5-(4-methylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
-
0.000058
N-[[5-(4-methylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Sus scrofa
-
IC50: 0.000058 mM
0.000041
TAPI-2
Homo sapiens
-
mutant enzyme V353G
0.000043
TAPI-2
Homo sapiens
-
wild type enzyme
0.000013
tert-butyl (5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)carbamate
Sus scrofa
-
-
0.000013
tert-butyl (5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)carbamate
Sus scrofa
-
IC50: 0.000013 mM
0.000047
tert-butyl 4-(5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)piperidine-1-carboxylate
Sus scrofa
-
-
0.000047
tert-butyl 4-(5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)piperidine-1-carboxylate
Sus scrofa
-
IC50: 0.000047 mM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.